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ABSTRACT 
Wenjie Lu 
Understanding Aromatase:   
A Mechanistic Basis for Drug Interactions and New Inhibitors 
 
Aromatase is the cytochrome P450 enzyme that converts androgens to estrogens. 
Aromatase is the target of the aromatase inhibitor class of drugs widely used to treat 
estrogen-mediated conditions including breast cancer. Little is known about the role of 
this enzyme in drug metabolism or in drug interactions. Since this lack of knowledge has 
been an impediment to optimal therapy, it is important to understand these roles of 
aromatase. Therefore, a comprehensive series of studies was carried out to characterize 
its ability to metabolize drugs and its susceptibility to inhibition by xenobiotics. The 
overall objective of this work was to better understand the interactions of small molecules 
with aromatase and to use this new knowledge to predict aromatase-mediated drug 
interactions and anticipate novel molecular structures that interact with the enzyme.  
Aromatase was shown to be a drug metabolizing enzyme able to metabolize 
methadone both in vitro (Km of 314 μM) and in vivo (22% of methadone clearance). A 
number of novel aromatase inhibitors that employ diverse kinetic mechanisms were 
identified. These include a potent competitive inhibitor: norendoxifen (Ki of 35 nM), two 
non-competitive inhibitors: endoxifen (Ki of 4.0 μM) and N-desmethyl-tamoxifen (Ki of 
15.9 μM), a mechanism-based inhibitor: methadone (KI of 40.6 ± 2.8 μM; kinact of 0.061 
± 0.001 min-1), and a stereoselective inhibitor: naringenin (IC50s of 2.8 μM for (R)-
enatiomer and 1.4 μM for (S)-enatiomer). Through investigation of the structure-potency 
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relationships so discovered, a series of new biochemical structures to be exploited as 
aromatase inhibitors were identified.   
These studies have identified new roles for aromatase as a catalyst for methadone 
metabolism and as a mediator of the effects of tamoxifen by demonstrating that a number 
of its metabolites can act as aromatase inhibitors. This work also provides a new 
mechanistic framework for the design of novel aromatase inhibitors that can be used in 
breast cancer. Overall, the data suggest ways to more consistently treat breast cancer with 
current medications, to better anticipate drug interactions, and therefore to improve the 
quality of life of patients in ways that minimize side effects, while optimizing therapeutic 
benefits, in each person treated. 
 
David A. Flockhart, M.D., Ph.D., Chair   
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 CHAPTER ONE 
Introduction and Literature Review 
 
The cytochrome P450 enzyme family 
The cytochrome P450s (CYPs) are a superfamily of enzymes. These enzymes all 
contain a molecule of heme non-covalently bound to the polypeptide chain. CYPs use O2 
and H+, which is derived from the cofactor reduced nicotinamide adenine dinucleotide 
phosphate (NADPH), to carry out the oxidative metabolism of a number of endogenous 
and exogenous compounds like steroids, bile acids and drugs. In humans, there are more 
than 50 individual CYP isoforms (Gonzalez and Tukey 2006). The CYP genes with 
known functions are expressed in the endoplasmic reticulum of a number of tissues 
(Nelson et al. 2004). Human liver expresses important drug-metabolizing CYPs, 
including CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1, CYP3A4 and CYP3A5. These are the most actively studied of the drug-
metabolizing enzymes since they are the responsible for metabolizing the vast majority of 
therapeutic xenobiotics (Gonzalez and Tukey 2006).  
The activities of these CYPs determine the rate of biotransformation of a parent 
substrate into active and/or inactive metabolites. This process influences several 
subsequent outcomes including the concentration of the substrate and its metabolites that 
will be achieved in the body and the rate of their elimination from the body. The CYPs 
that catalyze steroid and bile acid synthesis have very specific substrate preferences. In 
contrast, the CYPs that carry out xenobiotic metabolism have the capacity to bind and 
metabolize a large number of structurally diverse chemicals. A single compound can also 
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be metabolized by different CYPs. This extensive overlapping of substrate specificities is 
one of the underlying causes for the predominant clinical pharmacokinetic drug-drug 
interactions. For example, when two coadministrated drugs are both metabolized by the 
active site of the same CYP, they compete for the binding site. As a result, the 
metabolism of one or both drugs may be inhibited and this can lead to increased clinical 
exposure to the parent drug and decreased exposure to the metabolites. The activity of 
CYPs can also be influenced by factors other than co-medication, including 
environmental and genetic factors.  
 
Aromatase and its role in steroidogenesis 
The CYP that converts androgens to estrogens is CYP19, also known as 
aromatase (Chen 1998). Aromatase has been recognized as a key enzyme in 
steroidogenesis as it is the only enzyme responsible for the demethylation and subsequent 
aromatization of testosterone to estradiol and androstenedione to estrone.  
 
Aromatase expression and variability in aromatase activity 
Unlike most of the important CYPs, aromatase is not highly expressed in healthy 
human livers (Carruba 2009) and hepatic aromatase activity is minimal. In 
premenopausal women, aromatase activity is high in the ovaries. Estrogens produced in 
the ovaries are important hormones that can circulate and act on distal estrogen receptors 
in the target tissues. In postmenopausal women and men, estradiol is primarily 
synthesized in extragonadal tissues where it also serves locally as a paracrine, autocrine 
or intracrine factor. Aromatase is expressed in these extragonadal sites including 
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osteoblasts and chondrocytes of bone, mesenchymal cells of breast and other adipose 
tissue, the vascular endothelium, aortic smooth muscle cells, and numerous sites in the 
brain (Simpson 2003).  
Aromatase is coded by the gene CYP19A1, which is located on chromosome 
15q21.1 in humans. This gene spans 120 kb and it has a large and complex upstream 
regulatory unit comprising untranslated exon I and a number of promoters, and a 30 kb 
coding region consisting of nine translated exons II to X (Simpson 2003). Untranslated 
exon I is associated with at least 10 different tissue–specific promoters. Since the exon I 
is not translated, the translated protein product are identical in all the tissues. Each tissues 
utilizes its own promoters and associated enhancers and suppressors to express a unique 
untranslated first exon 5’-UTR (Simpson and Davis 2001; Sebastian and Bulun 2001; 
Bulun et al. 2003). This differential splicing process leads to different amounts of mRNA 
transcripts, differences in mRNA stability and protein translation (Simpson and Davis 
2001; Santen et al. 2009; Wang, Li, and Hu 2009). As a result, this process defines the 
tissue-specific regulation of aromatase activity and estrogen biosynthesis.  
Since aromatase expression is present in many tissues and its regulation is 
complex, the enzyme activity has been shown to vary with a lot of factors including 
gender (Labrie et al. 1997), menstrual cycle (Sano et al. 1981), age (Labrie et al. 1997; 
Grow 2002), weight (Yousefi et al. 2011) and ethnicity (Marsh et al. 2011). The enzyme 
activity is also influenced by genetic variants. The most widely studied is a 
tetranucleotide (TTTA)n tandem repeat polymorphism located in intron 4 of the human 
CYP19A1 gene, and it has been reported that the number of TTTA repeats is associated 
with estrogen concentrations and risks for several estrogen-regulated diseases (Somner et 
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al. 2004; Gennari et al. 2004; Ahsan et al. 2005; Kristensen et al. 2000; Masi et al. 2001). 
There have also been a few reports of a rare autosomal recessive disease, human 
aromatase deficiency, caused by loss-of-function mutations in the CYP19A1 gene (Bulun 
2000; Belgorosky et al. 2009; Rochira and Carani 2009). In addition, aromatase activity 
may be influenced by many extrinsic factors such as herbal supplements (Wang et al. 
2009), red wine (Eng et al. 2003), calcitriol (Krishnan and Feldman 2011), myosmine 
(Doering and Richter 2009), and environmental toxins like phthalates (Toda et al. 2003). 
 
Aromatase as a target of endocrine therapy for breast cancer 
Aromatase expression and activity has been shown to be enhanced in various 
cancers, including breast tumors, hepatocellular carcinoma, adrenocortical tumors and 
testicular tumors (Bulun and Simpson 2008; Jongen et al. 2006; Carruba 2009; Bulun et 
al. 1997; Young et al. 1996; Aiginger et al. 1981). Local paracrine and/or intracrine 
estrogen signaling is believed to stimulate the progression and recurrence of the disease, 
particularly in the case of breast cancer. About 70 - 80% of all newly diagnosed breast 
cancers are positive for the estrogen receptor (Hammond et al. 2010). The total number 
worldwide is more than one million every year. Peripheral estrogen synthesis by 
aromatase is the primary pathway for the production of estrogen in women after ovarian 
function subsides during menopause or after another pathological change or medical 
intervention that reduces or eliminates ovarian function. For this reason, the enzyme 
aromatase represents an important target of many therapies that are designed to treat post-
menopausal estrogen-dependent breast cancer by reducing estrogen concentrations, and 
thereby reducing the growth of breast tumors and patients’ risk for recurrent breast 
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cancer. Of note, in premenopausal women aromatase inhibitors do not suppress estrogen 
concentrations because their ovarian-pituitary feedback loop prevents effective 
suppression of the enzyme activity. In fact, aromatase inhibition has been an effective 
endocrine therapy for other estrogen-mediated conditions. For example, the enzyme can 
be valuably targeted as part of treatments for infertility in premenopausal women in 
whom reduction of systemic estrogen is used to stimulate pituitary function and increase 
ovarian function (Pritts 2010).   
Two classes of drugs have been effective and widely used in treating hormone 
receptor positive breast cancer (Burstein et al. 2010; Osborne, Zhao, and Fuqua 2000): 
aromatase inhibitors (AIs) and selective estrogen receptor modulators (SERMs). While 
AIs operate by reducing peripheral estrogen generation, SERMs reduce estrogenic effects 
by antagonism of estrogen binding to the estrogen receptors (Figure 1.1). The most 
widely used SERM, tamoxifen, reduces the risk for recurrence and mortality in women 
with estrogen-sensitive breast cancer by 40% (Early Breast Cancer Trialists' 
Collaborative Group 2005). Over the last decade, large definitive trials have 
demonstrated that therapy with AIs is more effective than tamoxifen treatment in both the 
metastatic and adjuvant settings, but the absolute benefit relative to tamoxifen is only 2-
4% (Cuzick et al. 2010). On the basis of trials such as these, AIs have become the 
standard of care for the treatment of endocrine-responsive breast cancer in post-
menopausal women. 
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Figure 1.1. Mechanism of action of aromatase inhibitors and SERM tamoxifen. 
The AIs reduce peripheral estrogen generation by blocking aromatase activity. The 
SERMs reduce estrogenic signaling by antagonism of estrogen binding to the estrogen 
receptors. Source: with permission from Smith et al. 2003 (see Appendix). 
 
Efficacy and toxicity profiles of current aromatase inhibitors 
There are three aromatase inhibitors currently on the market: the azoles, 
anastrozole (Arimidex™) and letrozole (Femara™), which are potent competitive 
inhibitors, and the steroidal compound, exemestane (Aromasin™), which is a 
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mechanism-based inhibitor. These are the third-generation AIs. They are more selective 
and more clinically efficacious than the first-generation AI aminoglutethimide and the 
second-generation AIs formestane, fadrozole and rogletimide (Smith and Dowsett 2003). 
All third generation AIs decrease circulating estrogen concentrations by at least ten-fold 
compared to concentrations before treatment in untreated postmenopausal women. They 
have also been shown in large clinical trials to reduce the risk for breast cancer 
recurrence in post-menopausal women with estrogen-sensitive breast cancer by about 
50% (Cuzick et al. 2010).  
Despite their efficacy, therapy with current AIs results in marked side effects that 
make the drugs difficult to tolerate for the 2 - 5 years required for effective breast cancer 
treatment (Figure 1.2). Toxicities are one of the major reasons for discontinuation of AIs, 
and the most common adherence-limiting toxicity is the AI-associated musculoskeletal 
syndrome, or AIMSS (Henry et al. 2008; Henry, Giles, and Stearns 2008; Crew et al. 
2007; Morales et al. 2004; Land et al. 2006). This syndrome consists of a constellation of 
musculoskeletal symptoms, including generalized arthralgias, trigger finger, digital 
stiffness, carpal tunnel syndrome, or tendinitis/tendinopathy that occur in the absence of 
any alternative reason for development of these symptoms, such as trauma, pre-existing 
rheumatoid arthritis, or other definable causes. Earlier studies suggest that AIMSS is the 
reason for recorded discontinuation in 10 - 20% of all patients taking an aromatase 
inhibitor (Henry et al. 2008; Land et al. 2006). In a more recent survey (1,199 women), 
about 60% patients experienced debilitating side effects and AIMSS was the reason for 
discontinuation in ~ 75% of those who stopped the drug (Zivian and Salgado 2008).  
  
8 
 
 
Figure 1.2. Side effects of current AIs reported by breast cancer patients. 
The AI-associated musculoskeletal toxicities such as muscle pain and bone pain were the 
reason for discontinuation in ~ 75% of those who stopped taking the drug. Source: with 
permission from Zivian and Salgado 2008 (see Appendix). 
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While the available AIs reduce the recurrence of breast cancer, they do not 
eliminate recurrence. About 50% of patients treated with AIs still developed recurrent 
cancer (Cuzick et al. 2010). Furthermore, the positive effects of AIs come at the price of 
numerous side effects, which reduce compliance with therapy, reduce the quality of life 
of breast cancer patients and also decrease overall disease-free survival 
(Oberguggenberger et al. 2011; Zivian and Salgado 2008; Ziller et al. 2009; Partridge et 
al. 2008; Hershman et al. 2010). In a recent systemic review and meta-analysis of seven 
randomized controlled trials that compared AIs with tamoxifen as primary adjuvant 
endocrine therapy in postmenopausal women (a total of 30023 patients), treatment with 
current AIs was found to be associated with increased odds of developing cardiovascular 
disease and bone fractures that were major causes of death in this patient population 
(Amir et al. 2011). These cumulative toxicities of current AIs significantly reduced the 
survival benefit to this therapy despite improvements in cancer-free survival. Thus, there 
remains a need for developing more tolerable and effective drugs with better risk/benefit 
profile as the next generation of AIs.  
Aromatase inhibition therapy has also been shown to be effective in the 
prevention of the first occurrence of breast cancer. In a study of 4560 postmenopausal 
women who were at moderately increased risk for breast cancer, therapy with one of the 
available AIs, exemestane, was associated with a 65% relative reduction in the annual 
incidence of invasive breast cancer (Goss et al. 2011). It follows that improved AIs that 
are less toxic and easier to take could be better treatment options in a preventive setting 
for women at risk.  
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In addition, aromatase inhibitors are being explored as therapies for a number of 
other estrogen-related conditions. A recent study suggested that aromatase inhibition 
could be utilized as a better therapy for refractory endometriosis-related chronic pelvic 
pain than conventional treatments (Abushahin et al. 2011).  
 
 Evidence suggesting a broader role for aromatase in xenobiotic disposition 
The conversion of androgens to estrogens by aromatase is a key step in 
steroidogenesis, but this may not be the only important role that this enzyme plays in 
humans. Although aromatase has been widely recognized as an enzyme that “has strict 
substrate requirements and does not participate in xenobiotic or drug metabolism” 
(quoted from Gonzalez and Tukey 2006), emerging evidence suggests that this enzyme 
may also interact with xenobiotics, such as medications, dietary compounds and even 
environmental toxins. The clinical relevance of these interactions remains unclear. 
 
Possible involvement in drug metabolism and drug interactions 
Placental aromatase is able to metabolize methadone (Nanovskaya et al. 2004), 
cocaine (Osawa et al. 1993), and buprenorphine (Deshmukh, Nanovskaya, and Ahmed 
2003) in vitro, but the role of aromatase in drug metabolism in general has not been 
carefully investigated. The biochemical mechanism by which aromatase catalyzes the 
metabolism of testosterone or androstenedione employs 3 moles of O2 and 3 moles of 
NADPH for every mole of estrogen generated, and it involves three successive 
hydroxylations of the 19-methyl group of the androgens followed by the removal of this 
methyl group (Simpson et al. 2002) (Figure 1.3). Since it has been shown that aromatase 
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is able to remove a methyl group from cocaine and buprenorphine, it follows that other 
medications of similar structure and class may also be aromatase substrates.  
 
 
Figure 1.3. Demethylation of testosterone by aromatase. 
Source: modified from Vaz 2003. 
 
Aromatase has activity in many tissues. Therefore it is possible that the aggregate 
of this activity contributes significantly to drug metabolism in vivo. For example, 
methadone is a drug that undergoes demethylation and that has large inter-individual 
variability in its clearance, and the enzymatic route by which this reaction occurs in the 
human body is controversial (Shiran et al. 2009). Women metabolize methadone faster 
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than men (Baselt and Casarett 1972), and methadone clearance is significantly increased 
during pregnancy, when placental aromatase has high activity (Flockhart et al. 2009; 
Nanovskaya et al. 2004). This evidence all points to a possible role for aromatase in the 
metabolism of methadone and other drugs subject to demethylation. 
Since it is possible that aromatase contributes to human drug metabolism, co-
administration of aromatase inhibitors, particularly in patients with breast cancer, may 
result in pharmacokinetic drug-drug interactions that decrease the elimination of those 
drugs metabolized by aromatase and thereby lead to unfavorable pharmacodynamic 
effects at standard doses.  
Aromatase inhibition may also alter the metabolism of endogenous testosterone 
and androstenedione. This change might lead to indirect effects on up- or down-
regulation of gene expression brought about by changes in the androgen and estrogen 
signaling pathways. These effects include the regulation of the expression of other drug 
metabolizing enzymes, drug transporters and even receptors, all of which might in turn 
contribute to undesirable drug side effects and/or alterations in drug disposition. It 
follows that aromatase may play an important role in drug metabolism and drug 
interactions. 
 
The active search for new aromatase inhibitors 
Since the current AIs are drugs that inhibit aromatase activity in the human body 
by binding to the active site of the enzyme, it is possible that other xenobiotics might also 
affect the enzyme activity in the similar way. The currently available AIs (letrozole, 
anastrozole, and exemestane) bring about side effects that limit patients’ compliance with 
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treatment (Hershman et al. 2010; Ziller et al. 2009; Partridge et al. 2008), and thus cause 
higher rates of breast cancer recurrence (Thompson et al. 2010). As a result, there is a 
recognized need for next generation inhibitors (Muftuoglu and Mustata 2010).  
A large number of investigators have invested significant effort in the search for 
novel structures and mechanisms that bring about adequate aromatase inhibition, while 
limiting side effects. More than a decade ago, a chemopreventive synthetic retinoid was 
reported to inhibit aromatase activity (Ciolino, Wang, and Sathyamoorthy 2000). Later, 
researchers found that phytochemicals in white button mushrooms, especially the 
unsaturated fatty acids linoleic acid and linolenic acid, have anti-aromatase activity (Chen 
et al. 2006). More and more studies have emerged in the last two years. Ellagitannins, a 
class of compounds found in pomegranate fruit, were extracted and tested, and 
derivatives were reported as potential aromatase inhibitors (Adams et al. 2010). Retinol 
and all-trans retinoic acid and several 7-substituted-4-imidazolylflavans based on the 
structure of natural flavonoids were shown to interact with aromatase (Yahiaoui et al. 
2011; Ciolino, Dai, and Nair 2011). Resveratrol and a series of synthesized new 
resveratrol analogues were characterized for their ability to inhibit aromatase, and one 
compound was suggested as a new promising aromatase inhibitor (Sun et al. 2010). This 
search remains active, and in contrast to conventional thinking, it is clear that aromatase, 
a catalyst of endogenous steroid metabolism, has the structural ability to interact with a 
large number of xenobiotics.  
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Summary  
Aromatase is an important cytochrome P450 enzyme that converts androgens to 
estrogens. Since estrogens drive breast cancer proliferation, aromatase is also the target of 
the aromatase inhibitor class of drugs used to treat breast cancer. While the available AIs 
are effective, they bring about severe side effects that reduce the quality of life of breast 
cancer patients, reduce compliance with therapy and also cause cardiovascular and 
musculoskeletal toxicities, which bring down the overall survival of breast cancer 
patients. There is a need for effective and more tolerable drugs with better risk/benefit 
profile as the next generation of aromatase inhibitors.  In addition, little is known about 
the role of aromatase in xenobiotic drug metabolism, or in drug interactions. As a result, 
optimal therapy with AIs could be compromised by unpredictable adverse events and 
reductions in efficacy that result. 
 
Research aims 
My long-term goal is to improve the treatment of breast cancer by optimizing the 
use of medications in ways that minimize side effects, while optimizing therapeutic 
benefits, in each person treated. The primary objective of my work is to better understand 
the interactions of small molecules with aromatase and to use this new knowledge to 
predict aromatase-mediated drug interactions and anticipate novel molecular structures 
that interact with the enzyme. Since aromatase is able to remove a methyl group from 
androgens to generate estrogens, I selected for study a group of drugs that (1) similarly 
undergo demethylation, and (2) are commonly prescribed to breast cancer patients and 
therefore are clinically relevant. 
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The overall hypothesis of this work is that aromatase interacts with a group of 
selected xenobiotics and therefore plays important roles in xenobiotic disposition and 
action in breast cancer. The specific objective of this research is to investigate 1) the 
ability of aromatase to metabolize drugs and possible involvement in pharmacokinetic 
drug-drug interactions that may result in significant clinical effects; 2) the effects of a 
selected series of xenobiotic compounds and their metabolites on aromatase activity. The 
specific objective will be tested through the following specific aims:  
Specific aim 1: To test the ability of aromatase to metabolize methadone and 
determine its quantitative contribution to methadone clearance in humans.  
Specific aim 2: To test the ability of a select group of compounds to inhibit 
aromatase activity.  
 
Significance  
The studies described herein may have clinical implications. Breast cancer is the 
most common cancer in women and one of the leading causes of death worldwide (Ferlay 
et al. 2010), and aromatase inhibitors are widely used as effective agents in the treatment 
of this disease. The translational relevance of this work includes new insights into drugs 
that are metabolized by aromatase, and that interact with it as inhibitors, and these 
findings have the potential to improve the use of methadone, and of the AI class of drugs, 
both of which are commonly co-prescribed with a wide range of other medications. As a 
result, it may be possible to more consistently treat breast cancer with current 
medications, and to better anticipate drug interactions. It also provides new insights into 
xenobiotic-aromatase interactions that illuminate potential alternative AIs. 
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Overall, this study could allow a better understanding of the involvement of 
aromatase in xenobiotic disposition and effects. This research will create a robust 
scientific knowledge base upon which to build future studies that address the importance 
of aromatase as a target for drug interactions, and that improve the rational prescribing 
database involving aromatase inhibitors.  
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CHAPTER TWO 
Metabolism of Methadone by Aromatase In Vitro 
 
Introduction  
Methadone is a synthetic analgesic that is distinguished by its long duration of 
action, a property that makes it ideal for the treatment of chronic pain and for opioid 
withdrawal (Fredheim et al. 2008). Prescriptions in the United States have grown by 
1300% between 1997 and 2006 (Kharasch et al. 2009), primarily as the result of 
increasing use as a first-line analgesic. In addition, methadone maintenance therapy is the 
mainstay for the treatment of opioid addiction, but it is estimated that fewer than 10% of 
individuals who are addicted to heroin and prescription opioids are actually receiving 
methadone (Kleber 2008).  
Despite its advantages and widespread utility, the use of methadone is limited by 
complex pharmacokinetic characteristics that include a long elimination half-life and 
susceptibility to pharmacokinetic drug-drug interactions (Weschules, Bain, and 
Richeimer 2008). The goal of predictable, reproducible and effective dosing is 
confounded by considerable inter-individual variability in methadone pharmacokinetics, 
particularly in its clearance (up to 100-fold, Totah et al. 2008). This variability is further 
complicated by stereoselectivity in methadone pharmacokinetics. While methadone is 
generally administered as a racemic mixture, consisting of equal amount of two 
enantiomers; the (R)-, levo-, 1-or (+) and the (S)-, dextro-, d- or (-) methadone, these 
enantiomers differ in pharmacokinetic and pharmacodynamic properties. The 
unpredictability of methadone’s effects due to these multiple characteristics results in a 
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high incidence of over- and under-dosing. Inappropriate dosing can clearly cause severe 
adverse events such as withdrawal symptoms, respiratory depression, and 
electrocardiographic QT interval prolongation that can result in sudden cardiac death 
(Sims, Snow, and Porucznik 2007; Kharasch et al. 2009; Kalgutkar, Obach, and Maurer 
2007; Krantz et al. 2003). 
Although methadone has been used for more than seventy years, the metabolism 
of methadone in the human body is still not fully understood and the effective and safe 
dose among patients is highly variable. It is suspected that the variability in methadone 
clearance and the frequent under- or over-dosing are results of a wide distribution of the 
rate of methadone metabolism. The metabolism of methadone to its primary 
demethylated metabolite, EDDP, and then to its secondary metabolite, EMDP (Figure 
2.1), is well documented as the major metabolic pathway (Pohland, Boaz, and Sullivan 
1971; Sullivan and Due 1973), but the enzymatic route by which these reactions occur in 
the body is controversial (Shiran et al. 2009). Since understanding of the metabolic 
pathways responsible for drug interactions or environmental effects is incomplete 
(Weschules, Bain, and Richeimer 2008), it is difficult to predict methadone 
pharmacokinetics, and adverse events during methadone therapy are frequent. Patients 
taking methadone are often co-prescribed many other medications and are therefore 
vulnerable to drug-drug interactions (Weschules, Bain, and Richeimer 2008). Poorly 
understood drug-drug interactions may thus contribute to the notable increase in 
methadone-related deaths (Sims, Snow, and Porucznik 2007) that has attended the 
increase in the drug’s use over the past decade (Kharasch et al. 2009).  
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Figure 2.1. Dominant route of methadone metabolism.  
Methadone is N-demethylated to the primary metabolite, EDDP, and EDDP is further N-
demethylated to the secondary metabolite, EMDP. Source: drawn based on results from 
(Sullivan and Due 1973).  
 
There is a need to improve our understanding of methadone metabolic pathways.  
While potential interactions with methadone via CYP3A and CYP2B6 have been 
carefully studied in vitro (Iribarne et al. 1997; Foster, Somogyi, and Bochner 1999; Wang 
and DeVane 2003; Kharasch et al. 2004) and in vivo (Eap, Buclin, and Baumann 2002; 
Totah et al. 2008), it is clear that these enzymes cannot fully explain the large variability 
in methadone pharmacokinetics. Other potential routes of metabolism may be important. 
Previous studies suggested that placental aromatase may be responsible for the increased 
methadone clearance in pregnant women (Hieronymus et al. 2006; Nanovskaya et al. 
2004). However, drug interactions involving drugs that alter methadone clearance via 
aromatase have not been described or tested for. Patients with metastatic breast cancer 
who are in pain may often be co-prescribed methadone with a potent aromatase inhibitor, 
and may therefore be at risk for interactions between these two drugs. To better 
understand the role aromatase plays in methadone metabolism, I tested the hypothesis 
that aromatase is able to metabolize methadone to its primary metabolite, EDDP. 
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Results 
The ability of recombinant human aromatase to metabolize methadone was tested 
using microsomal incubations in vitro. The metabolism of methadone by pooled human 
liver microsomes (HLMs) was used as a positive control. Metabolism of methadone 
(1000 µM) to EDDP by both recombinant human aromatase and HLMs was observed 
(Figure 2.2). A selective aromatase inhibitor, letrozole, was used to completely block 
aromatase activity as a control. In human liver microsomes, letrozole (50 nM) lowered 
EDDP formation from methadone (10 µM) by ~ 7%, whereas in recombinant aromatase 
letrozole at this concentration reduced EDDP formation by ~ 65%. Most important of all, 
the enzyme in the recombinant aromatase microsomal preparation that converts 
methadone to EDDP was confirmed to be aromatase because the conversion of 
methadone to EDDP was completely inhibited by 1 µM of letrozole. 
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Figure 2.2. Both human liver CYP enzymes and aromatase can contribute to the 
primary metabolism of methadone. 
Percent of EDDP formation from methadone relative to controls without letrozole 
(Columns 1 and 3 from the left). Human liver or recombinant aromatase microsomal 
preparations were incubated with methadone (10 µM) for 30 min at 37 oC and the amount 
of EDDP generated was determined by LC-MS/MS. 
 
The logical next step was to characterize the metabolism of methadone by 
aromatase and these experiments were then carried out under conditions where secondary 
metabolism from EDDP to EMDP was not detected. Figure 2.3 depicts the rate of EDDP 
generation from methadone across a range of methadone concentrations (0 - 2000 µM). 
These data indicate metabolism of methadone to EDDP by recombinant human 
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aromatase with a Km of 314 µM and a Vmax of 7.6 pmol/min/pmol of P450. When the 
(R)- and (S)-enantiomers of methadone were separately tested, no stereoselectivity was 
observed (Figure 2.4). 
 
 
 
Figure 2.3. Michaelis-Menten kinetics of methadone metabolism by recombinant 
human aromatase. 
A range of racemic methadone concentrations was incubated with recombinant aromatase 
(0.05 µM) for 30 min, and the amounts of EDDP generated were determined using HPLC 
in three independent experiments. Individual points represent the mean of duplicate 
incubations. 
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 Figure 2.4. Metabolism of methadone by human aromatase was not stereoselective. 
A range of (R)-methadone (dark square) or (S)-methadone (open diamond) 
concentrations was incubated with recombinant aromatase (0.05 µM) for 30 min, and the 
amounts of EDDP generated were determined using HPLC. Individual points represent 
the mean of duplicate incubations. 
 
Discussion  
The effective use of methadone in the treatment of pain and heroin addiction is 
compromised by poor understanding of the metabolic routes involved in its disposition. 
One direct consequence is the inability to anticipate drug interactions in patient 
populations who are commonly co-prescribed multiple medications. For years, 
methadone metabolism has been widely attributed to CYP3A4 (Iribarne et al. 1997), and 
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this body of science is reflected in the current FDA-approved label for methadone, which 
states in part:  
“Since the metabolism of methadone is mediated primarily by the 
CYP3A4 isozyme, coadministration of drugs that inhibit CYP3A4 activity 
may cause decreased clearance of methadone. Thus, methadone-treated 
patients coadministered strong inhibitors of CYP3A4, such as azole 
antifungal agents (e.g., ketoconazole) and macrolide antibiotics (e.g., 
erythromycin), with methadone should be carefully monitored and dosage 
adjustment should be undertaken if warranted.”  
 
The scientific basis of this recommendation has been challenged by recent clinical data 
that provide strong and unambiguous evidence against the involvement of this enzyme 
(Kharasch et al. 2008; Kharasch et al. 2009). An assessment of clinical CYP3A activity 
and methadone clearance in normal volunteers showed that CYP3A inhibition by 
ritonavir (a potent CYP3A4 inhibitor that caused > 90% inhibition) had no effect on 
methadone plasma concentrations or clearance (Kharasch et al. 2008). Variability in 
CYP3A4 activity also had modest influence on the oral clearance of methadone and its 
enantiomers (Shiran et al. 2009). Most notably, there was no correlation between 
intravenous methadone clearance and hepatic CYP3A activity, and none between oral 
methadone apparent clearance and first-pass CYP3A activity (Kharasch et al. 2009). This 
in vivo evidence strongly supports the notion that the role of CYP3A in clinical 
methadone clearance is not critical and that other CYPs may be more important.  
In our study, aromatase has been demonstrated as an alternative enzyme that is 
able to metabolize methadone. We showed that human recombinant aromatase 
metabolized methadone to the dominant metabolites that are observed in humans and that 
this conversion can be completely blocked by the selective aromatase inhibitor letrozole. 
These data are consistent with the earlier reports that suggest methadone metabolism by 
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human placental aromatase (Nanovskaya et al. 2004; Hieronymus et al. 2006). This 
finding may be important. First, it is possible that aromatase contributes to the clearance 
of methadone in vivo. However, our observed Km value in the recombinant system is 
high compared to plasma methadone concentrations within therapeutic range in patients 
(Eap, Buclin, and Baumann 2002), the clinical relevance of aromatase and the extent to 
which aromatase metabolizes methadone in general is unclear. Second, the data showing 
that methadone metabolism by HLMs was not substantially inhibited by letrozole are 
consistent with the fact that aromatase is expressed at a low level in human liver (Carruba 
2009). However, aromatase does have high activity in many other tissues (Simpson et al. 
2002), and methadone has a high volume of distribution that varies from 1.0 to 8.0 L/kg 
(FDA label for methadone) reflecting its distribution to many tissues. Therefore, 
metabolism of methadone by aromatase in tissues where methadone accumulates in vivo 
would seem possible. Fourth, since withdrawal from methadone is often idiosyncratic and 
is poorly understood, the possibility of patients having variable aromatase activity that 
leads to different rate of methadone elimination deserves further studies. With that said, 
methadone metabolism by other liver CYP450 enzymes could be largely responsible for 
the variability seen in methadone clearance, and the role of aromatase might be important 
in patients who either have low liver metabolism of methadone or have relatively high 
aromatase activity. In addition, since the biochemical aromatization of testosterone by 
aromatase is initiated by the removal of a methyl group, and since aromatase is also able 
to remove methyl groups from methadone, cocaine (Osawa et al. 1997), and 
buprenorphine (Deshmukh, Nanovskaya, and Ahmed 2003), it is possible that aromatase 
is involved in the demethylation of other drugs. 
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In summary, this study has shown that aromatase is able to demethylate 
methadone in vitro. The clinical relevance of this metabolic pathway, its quantitative 
contribution to methadone clearance in humans, and the involvement of aromatase in 
overall methadone disposition are unclear, and further studies that are designed to address 
these questions are discussed in the next chapter. 
 
Methods 
Methadone metabolism in vitro by recombinant aromatase 
All incubations were carried out as described in “Chapter Ten: General Methods / 
Testosterone and methadone metabolism in vitro by recombinant aromatase”. 
 
Quantification of EDDP formation 
High performance liquid chromatography (HPLC) assays with ultraviolet (UV) 
detection were developed for the quantification of methadone conversion to EDDP as 
described in “Chapter Ten: General Methods / HPLC-UV assays for the quantifications 
of estradiol and EDDP formation”.  
 
Kinetic analyses 
Formation rates of metabolite at different substrate concentrations were fit to 
appropriate enzyme kinetic models using SigmaPlot (Version 10.0, Systat software, Port 
Richmond, CA). Data were best fit to a one site Michaelis-Menten equation.  
 
Note: The work described in this chapter has been published (Lu et al. 2010). 
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CHAPTER THREE 
Metabolism of Methadone by Aromatase in Humans 
 
Introduction  
Methadone is of particular value to patients who require long-term treatment of 
chronic pain and opioid addiction. Despite its acknowledged value, methadone is subject 
to highly variable pharmacokinetics (Weschules, Bain, and Richeimer 2008; Eap, Buclin, 
and Baumann 2002). As a result initial dosing requirements and subsequent adjustments 
are difficult to anticipate, and inappropriate dosing can clearly cause severe adverse 
events (Modesto-Lowe, Brooks, and Petry 2010; Corkery et al. 2004; Latowsky 2006; 
Krantz et al. 2003). A rational approach to methadone dose estimation or adjustment 
during therapy based on the understanding of the pathways of methadone disposition still 
needs to be developed. Improved understanding of methadone disposition requires 
knowledge of the enzymes involved in its metabolism in humans. Many enzymes have 
been proposed to be involved, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP3A and aromatase (Kharasch et al. 2008; Kharasch et al. 2009; 
Shiran et al. 2009; Totah et al. 2008; Chang et al. 2011; Wang and DeVane 2003; 
Hieronymus et al. 2006), but few of these has been definitively demonstrated to be 
involved in vivo. For example, CYP2B6 plays an important role in methadone 
metabolism (Totah et al. 2008; Crettol et al. 2005; Wang et al. 2011) but CYP3A does 
not (Kharasch et al. 2008; Kharasch et al. 2009); yet, it is equally clear that CYP2B6 
cannot explain all of the variability in methadone disposition and effects (Chang et al. 
2011; Crettol et al. 2005). For this reason, other possibilities have been explored and a 
28 
 
number of lines of evidence point to the involvement of aromatase (Chapter One, this 
dissertation), an enzyme previously thought to be involved exclusively in endogenous 
steroidogenesis.  
My previous work has shown that methadone can be metabolized by recombinant 
human aromatase in vitro (Chapter Two, this dissertation). The metabolic routes involved 
in methadone disposition are unclear and previous studies in vitro suggest that 
metabolism by aromatase may contribute (Km of 314 µM, Vmax of 7.6 pmol/min/pmol of 
P450; single-site Michaels-Menden model). These data were determined in a 
recombinant system. It is difficult to extrapolate in vitro binding affinity to clinical 
predictions, especially with drugs such as methadone that are concentrated in tissues 
(Inturrisi et al. 1987). The contribution, if any, of aromatase to the metabolism of 
methadone in clinical settings has not been determined. The possibility exists that 
aromatase contributes significantly to the metabolism of methadone, and that the inter-
individual variability seen in methadone pharmacokinetics may be explained in part by 
variability in aromatase activity. 
Aromatase activity is highly variable. It is the enzyme responsible for the 
conversion of endogenous androgens to estrogens, and its regulation and expression have 
been the subjects of intense study (Simpson et al. 2002; Simpson 2003; Czajka-Oraniec 
and Simpson 2010). The activity of the enzyme varies considerably between men and 
women (Labrie et al. 1997), with age (Grow 2002; Labrie et al. 1997), with the menstrual 
cycle (Sano et al. 1981) and with weight (Yousefi et al. 2011). In addition, its activity 
may be influenced by many extrinsic factors including herbal supplements (Wang et al. 
2009), and calcitriol (Krishnan and Feldman 2011). In order to address whether or not 
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aromatase can metabolize methadone in humans, the ability of aromatase to demethylate 
methadone in tissues should be examined. Since aromatase is present in many tissues 
including adipose tissue, breast, bone, brain, liver and blood vessels (Simpson et al. 
2002), it is difficult, if not impossible, to assess the overall contribution of this enzyme to 
systemic drug clearance using in vitro studies conducted in any individual tissue. For this 
reason, clinical studies are the ideal means with which to address the involvement of 
aromatase in the elimination of methadone in a quantitative manner.  
Aromatase is the target of the aromatase inhibitor class of drugs now routinely 
used to reduce circulating estrogens in the treatment of breast cancer and a number of 
other conditions. The availability of these potent and selective aromatase inhibitors 
presents a valuable opportunity to study the disposition of drugs that might be 
metabolized by aromatase. Our study was designed to use the clinically available 
aromatase inhibitor, letrozole, to test the hypothesis that the metabolism of methadone in 
humans is altered by essentially complete aromatase inhibition.  
We designed a clinical trial and then carried it out in a group of postmenopausal 
women. We chose to study postmenopausal women because aromatase activity in general 
is higher in women than in men and aromatase inhibitors do not fully block aromatase 
activity in premenopausal women, in whom the ovarian-pituitary feedback loop prevents 
effective suppression of enzyme activity (Pritts 2010). After analysis of blood and urine 
samples collected during this trial, I present here the resulting data on the effects of 
letrozole on the disposition of methadone in this group. 
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Results 
The effects of aromatase inhibition on single dose methadone pharmacokinetics (2 
mg, intravenous) were studied in 15 healthy, post-menopausal women. The subjects 
studied were all healthy female and post-menopausal, with a mean age of 54, a mean 
weight of 84 kg and BMI of 30 (Table 3.1). The mean QTc (Bazette) interval at screening 
before their participation in the study was 413 msec. All 15 subjects enrolled completed 
the study according to the protocol. No serious adverse events or significant changes in 
vital signs (blood pressure, pulse, respiratory rate and pulse oximetry) were recorded.  
 
Table 3.1. Demographics of study population (n = 15). 
 
 
A sequential design was employed, involving a control period followed by 
treatment with letrozole (2.5 mg/day, 10 days) in which each subject served as her own 
control (see “Methods” section). The disposition of methadone after intravenous 
administration (2.0 mg) was altered by the treatment of letrozole. Mean plasma 
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concentrations of methadone and its primary metabolite, EDDP, before and after 
letrozole treatment, are shown in Figure 3.1. The calculated methadone and EDDP 
pharmacokinetic parameters derived from these data are displayed in Table 3.2. 
Methadone systemic clearance, plasma AUC, elimination half-life, and the ratio of 
plasma AUC of methadone to plasma AUC of EDDP during letrozole treatment were all 
significantly different from those derived from the data obtained after the first dose of 
methadone, administered during the control period. In contrast, there was no appreciable 
change in the methadone distribution half-life, volume of distribution or its estimated 
apparent 0 - 12 h renal clearance between the control and letrozole-treated periods. When 
the metabolite data from the two periods were compared, no appreciable difference was 
observed in the AUC of plasma EDDP concentrations, or in its estimated apparent 0 - 12 
h renal clearance (Table 3.2). The secondary metabolite of methadone, EMDP, was 
present at concentrations at least ten-fold lower than that of EDDP, and was not 
consistently detected in all plasma samples and so pharmacokinetic parameters for this 
metabolite could not be calculated.  
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Figure 3.1. Effects of letrozole treatment on intravenous methadone disposition.  
Plasma methadone (A) and EDDP (B) concentrations in the control (open diamond, dash 
line) and letrozole (closed diamond, solid line) periods are shown as the mean ± SD (n = 
15) on a logarithmic scale (base 10). Subjects received 2.0 mg intravenous methadone 
HCl (1.8 mg free base) in both periods. Variation in the actual time of plasma sampling 
was less than 5%.  
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Table 3.2. Pharmacokinetic parameters in the letrozole-treated period compared to 
control. 
 
Note: Data are presented as mean ± SD (n = 15). CLIV, systemic clearance; AUC, area 
under the plasma concentration-time curve; t½, half life; Vd, volume of distribution; CLr, 
renal clearance; Cbaseline, plasma concentration at baseline before methadone dosing. *, 
significantly different from control; P values were calculated using paired t-test (control-
letrozole). 
 
34 
 
Plasma concentrations of methadone during letrozole treatment were higher than 
those during the control period, with significant differences being noted after 48 h (Figure 
3.1.A). The concentration of EDDP was notably lower than that of methadone itself at all 
time points. There was no appreciable difference in plasma concentrations of the 
metabolite EDDP, before and after letrozole treatment (Figure 3.1.B). Both methadone 
and EDDP concentrations appeared to have large inter-individual variability (up to 3.0-
fold for methadone AUC0-∞ and 4.7-fold for EDDP AUC0-72 h, Figure 3.1 and Table 3.2). 
The effect of letrozole on systemic methadone clearance was highly variable. 
While one subject actually experienced a 17% increase in methadone clearance during 
letrozole treatment, three out of fifteen subjects changed 3% or less, and the majority 
(eleven) experienced decreases in methadone clearance that ranged from 11% to 51% 
with a mean of 27% (Figure 3.2). On average, letrozole treatment significantly reduced 
methadone clearance by 22% (p = 0.001, Figure 3.2.B and Table 3.2). Methadone 
clearance during the untreated control period ranged from 0.45 to 2.42 ml kg-1 min-1 (a 
5.4-fold variation, Figure 3.2.B), but there was no appreciable relationship between this 
control methadone clearance and the magnitude of the treatment effect that was observed 
(data not shown).  
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Figure 3.2. Effects of letrozole treatment on methadone systemic clearance. 
 (A) Each column represents the percent change of methadone clearance for an individual 
subject during letrozole treatment. (B) Data representing individual subjects are shown as 
grey circles, with lines connecting the control and letrozole periods. The means are 
shown as black squares (n = 15). Methadone systemic clearance was significantly 
different between the two periods (P < 0.05, paired t-test).  
36 
 
Changes in methadone AUC0-∞ and elimination half-life observed during letrozole 
treatment were also highly variable (Table 3.2). The AUC0-∞ increased an average of 23% 
(p = 0.007) and the elimination half-life increased an average of 21% (p = 0.042, Table 
3.2). In these subjects, methadone elimination half-life during the control period ranged 
from as short as 34 h to as long as 124 h (a 3.7-fold variation). The largest effect brought 
about by letrozole on elimination half-life was a 2.2-fold increase in one subject, from 34 
to 77 h. 
Over the 72 hours after methadone administration, the plasma AUC of methadone 
increased significantly during letrozole treatment (p = 0.003), while the plasma AUC of 
EDDP did not change (Table 3.2). The ratio of plasma AUC0-72 h values (methadone / 
EDDP) increased significantly during letrozole treatment compared to control (p = 0.009, 
Table 3.2). There was also an increase on average in the methadone to EDDP ratio in the 
urine collected over the first 12 h after methadone administration, but the difference was 
not significant due to large interindividual variability (Table 3.2). When the observed 
change in the ratio of plasma AUC0-72 h values (methadone / EDDP) was plotted against 
the observed change in plasma methadone AUC0-∞, there was a linear relationship with a 
R2 value of 0.74 (Figure 3.3.A), suggesting an association between the decreased rate of 
methadone metabolism and its decreased systemic clearance. These data indicate that the 
metabolism of methadone to EDDP was diminished during letrozole treatment. In 
contrast, there was no obvious association between change in plasma methadone AUC0-∞ 
and change in apparent 0 - 12 h urinary methadone clearance (Figure 3.3.B), suggesting 
that alterations in renal elimination rate of methadone were not the primary cause of the 
observed decrease in methadone clearance. 
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Figure 3.3. Letrozole treatment decreased methadone clearance via inhibition of the 
metabolism of methadone to EDDP. 
 (A) Association (R2 = 0.74) between change in plasma methadone AUC0-∞ and change in 
the ratio of plasma methadone to EDDP (AUCmethadone, 0-72 h / AUCEDDP, 0-72 h). (B) No 
association between change in plasma methadone AUC0-∞ and change in apparent 0 - 12 
h urinary methadone clearance. 
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Plasma letrozole concentrations at baseline before the administration of the 
second methadone dose were measured. After taking 2.5 mg letrozole daily for 8 days, all 
subjects had letrozole concentrations within the expected range, indicating that no 
subjects were non compliant. The average plasma letrozole concentration was 157 ng/ml, 
with a minimum of 80 ng/ml and a maximum of 257 ng/ml (Table 3.2). There was no 
appreciable association between letrozole concentration and any of the observed changes 
in methadone pharmacokinetics (data not shown). 
 
Discussion  
In this study we observed a significant decrease in the clearance of methadone 
during the coadministration of letrozole. This decrease was accompanied by significant 
increases in the methadone AUC, in its half-life and in the parent to metabolite ratio in 
plasma. These effects are all consistent with a decrease in methadone metabolism brought 
about by letrozole. Since letrozole is a highly selective inhibitor of aromatase at the given 
dosage, these data are also consistent with the possibility that some fraction of methadone 
metabolism is mediated via aromatase. 
Aromatase has been implicated in the metabolism and specifically the 
demethylation of a number of drugs in vitro, including methadone (Chapter Two, this 
dissertation), buprenorphine (Deshmukh, Nanovskaya, and Ahmed 2003) and cocaine 
(Osawa et al. 1997), but the role that this enzyme plays in the metabolism of xenobiotic 
medications in humans has not been directly examined before in a clinical study. Our 
clinical trial presented here directly examined the involvement of this enzyme in 
methadone metabolism using selective aromatase inhibition as a tool. While aromatase is 
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already well recognized as being important in steroidogenesis, these data suggest for the 
first time a broader clinical role for this enzyme in the disposition of xenobiotic 
medications. Specifically, the ability of aromatase to catalyze N-demethylation of 
methadone in vivo suggests that it may be able to mediate the clearance of other drugs via 
a similar biochemical mechanism.  
Our data indicate that aromatase is responsible for ~ 22% of the clearance of a 2 
mg dose of methadone on average in a group of post-menopausal women (Table 3.2). 
Since aromatase may be a high capacity and low affinity enzyme for methadone 
metabolism, the quantitative contribution of aromatase to methadone disposition at higher 
doses remain unclear and deserves further studies. These findings suggest that breast 
cancer patients taking methadone who also take aromatase inhibitors may need 
appropriate dose adjustment to prevent methadone overexposure. Aromatase may also be 
important in the disposition of methadone in other populations, and may be in part 
responsible for the large and unpredictable variability in methadone clearance. Higher 
aromatase activity in premenopausal women may result in greater methadone clearance 
as a result. Men have less aromatase than premenopausal women and may consequently 
have lower clearance and higher exposure. Lastly, a quantitatively important role for 
aromatase in drug metabolism raises the possibility of clinically meaningful drug-drug 
interactions with aromatase inhibitors that would not otherwise have been anticipated. 
Such interactions might reasonably occur in patients taking aromatase inhibitors for a 
wide range of indications, including breast cancer, the treatment of infertility (Pritts 
2010) and their off-label use in testosterone augmentation regimes (Leder et al. 2004; 
Saylam, Efesoy, and Cayan 2011). 
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Alternative explanations for these findings exist. First, although letrozole is a 
potent and selective aromatase inhibitor at low concentrations, it is metabolized by 
CYP2A6 (Kamden et al. 2011) and has been shown to be able to inhibit CYP2A6 in vitro 
(Jeong et al. 2009). This inhibition has not been demonstrated in vivo. While it is possible 
that letrozole might inhibit CYP2A6 activity in vivo, a change in methadone metabolism 
due to inhibition of CYP2A6 seems unlikely because potent inhibition of CYP2A6 by 
coumarin in human liver microsomes did not inhibit methadone metabolism (Foster, 
Somogyi, and Bochner 1999). It seems unlikely that CYP2A6 plays a role in methadone 
metabolism in vivo. Second, it is possible that the effect of letrozole is not simply the 
result of direct inhibition of aromatase, but is rather the result of indirect transcriptional 
down regulation of either aromatase itself, or of CYP2B6 brought about via reductions in 
estrogen. Although CYP2B6 has been reported to be sensitive to estrogen-receptor 
dependent regulation in vitro, this has not been consistently reported across all cell lines 
(Lo et al. 2010; Mnif et al. 2007). It remains possible that CYP2B6 is down-regulated in 
the presence of low estrogen concentrations, and that this results in alterations in 
methadone pharmacokinetics, but this important possibility has not been investigated 
either in human hepatic preparations or in vivo.  
Of note, the effects of letrozole on methadone clearance were highly variable 
(Figure 3.2.A). Since aromatase activity varies among people, the variable response we 
observed may be in part due to variability in the contribution of aromatase to overall 
methadone metabolism. We also observed large variability in urinary methadone 
elimination (Figure 3.3.B). In particular, one subject who experienced a 17% increase in 
methadone systemic clearance during letrozole treatment also experienced a large 
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increase in urinary methadone elimination. Surprisingly, this subject had an increase in 
the parent to metabolite ratio in the urine, consistent with decreased metabolism. These 
data suggest that variability in both metabolism and urinary elimination contribute to the 
overall variability in methadone clearance.  
The data illuminate a number of possible underlying mechanisms. First, a number 
of mechanisms could contribute to variability in the inhibitory effects of letrozole on 
methadone metabolism. While variability in plasma letrozole concentrations could in 
theory bring about variability in inhibitory effect, our data indicate no relationship 
between letrozole plasma concentration and the extent of change in methadone 
pharmacokinetics. We would expect this to be the case given the documented high 
potency of letrozole. In addition, no relationship was observed between the initial 
methadone clearance during the control period and the extent of change observed, 
suggesting that the quantitative contribution of aromatase to methadone metabolism in 
individual subjects does not associate with the undisturbed metabolic rate. It is likely that 
there is a balance between aromatase and other enzymes suggested to be important in the 
metabolism of methadone, including particularly CYP2B6. This balance can vary among 
people, and therefore variability in the percent contribution of aromatase to overall 
methadone clearance might exist. It remains possible that the difference in response could 
be explained by pharmacogenomic variability in aromatase, or of CYP2B6 (Payne et al. 
2009; Mao et al. 2011; Ma et al. 2005; Ma et al. 2010; Crettol et al. 2005; Wang et al. 
2011). While the current study does not have sufficient power to ascertain the influence 
of such genetic factors, this possibility deserves further study.  
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Second, variability in urinary methadone elimination could be due to the well 
documented influence of urinary pH on the renal elimination of methadone (Nilsson et al. 
1982), but may also be the result of effects of letrozole on renal transporters as yet 
undescribed. In addition, both metabolic and renal clearance could also be influenced by 
the presence of other drugs or herbal medications taken by the subjects under study via 
mechanisms as yet unknown. Our current inability to predict methadone dose may thus 
be due to poor understanding of factors that influence a complex series of methadone 
elimination mechanisms, including at least two metabolic pathways: aromatase and 
CYP2B6 as well as variable renal elimination. 
Third, it is also possible that variability in the clinical disposition of drugs like 
methadone during concomitant treatment of aromatase inhibitors can be explained in part 
by genetic polymorphisms in the estrogen signaling pathways downstream of aromatase. 
Since estrogen is key to the regulation of the expression of a wide range of proteins, 
medications that directly affect estrogen synthesis by inhibiting aromatase may result in 
pharmacokinetic drug interactions via changes in proteins responsible for the absorption, 
distribution, metabolism and elimination of a specific drug, such as methadone. This 
estrogen-mediated influence on methadone disposition may be highly variable because of 
clinical effects of genetic polymorphisms in estrogen receptors and/or in the subsequent 
regulation of the expression of drug transporters, enzymes, binding proteins or drug 
receptors. The use of aromatase inhibitors therefore needs to be cautious not only in 
situations where alterations in direct metabolism of another drug by aromatase can 
happen. Indirect alterations in the expression of the proteome as the result of estrogen 
depletion may also lead to changes in drug clearance and exposure. 
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This trial has the following limitations. First, although methadone was given as a 
racemic mixture, we did not measure the individual (R)- and (S)-enantiomers. Although it 
is possible that changes in individual enantiomers may be obscured by this approach, our 
prior in vitro data using recombinant human aromatase clearly indicated that the 
metabolism of methadone by aromatase is not stereoselective, and we would therefore 
expect both enantiomers to be affected equally by the inhibition of aromatase in the 
subjects studied. Second, the urinary collection time was short (12 hours) relative to the 
long half-life of methadone, and this limits our ability to most accurately measure the 
urinary clearance of methadone or EDDP. While this is an important caveat, it does not 
compromise our ability to accurately determine the other pharmacokinetic parameters, all 
of which are internally consistent, and indicate a decrease in systemic clearance, and a 
prolongation of methadone half-life associated with reduced metabolism to EDDP. 
In summary, aromatase seems to account for ~ 22% of methadone clearance when 
the drug is given at a low dose in post-menopausal women. An involvement of aromatase 
in the metabolism of methadone suggests a broader role for this catalyst of endogenous 
steroid metabolism in xenobiotic drug disposition, and may help explain the difficulty in 
dosing methadone. Mechanisms underlying the variability in methadone clearance in 
response to letrozole treatment merit future studies. It is likely that human methadone 
metabolism is carried out by both aromatase and CYP2B6. Variability in methadone 
metabolism could thus be vulnerable to genetic factors that influence the activity or the 
regulation of either or both of these enzymes.  
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Methods 
Clinical protocol 
The study was approved by the Indiana University Institutional Review Board, 
and was conducted in the Indiana Clinical Research Center. All subjects signed informed 
consent before participation in the trial, and all procedures were conducted in accordance 
with the guidelines of the Declaration of Helsinki. Subjects enrolled in this clinical trial 
were healthy post-menopausal women 45 to 70 years of age who weighed at least 110 
lbs, and who agreed to avoid the use of alcohol during the period of the study. Potential 
subjects were excluded from the study if they had a history of intolerance or allergy to 
methadone or letrozole, had a known history of addiction to drugs, had a diagnosis of 
asthma, chronic obstructive pulmonary disease, cor pulmonale, severe obesity with a 
weight over 300 lbs, or sleep apnea syndrome. Subjects were also excluded if they were 
anemic (hematocrit below 30%), suffered from renal insufficiency (serum creatinine 
greater than 1.4) or had elevation of serum liver enzymes, had low serum potassium, a 
prolonged electrocardiographic QTc interval of more than 480 msecs (Bazette), were 
taking drugs know to prolong the QT interval or participated in a study within the last 
two months.  
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Figure 3.4. Clinical trial design and schedule of activities (n = 15). 
Blood samples (10 ml each) were collected before and at 1, 2, 4, 8, 12, 24, 48 and 72 
hours after every methadone dose. Urine samples were collected at baseline and over the 
first 12 hours after every methadone dose. 
 
The study protocol was a single-site, acute dose, 2-period sequential design with 
each subject as their own control (Figure 3.4, control period first). (1) Control period: 
Subjects were instructed to fast overnight for at least 8 hours before the first day of the 
study. On study day 1, following predose blood and urine sampling and the insertion of a 
forearm intravenous catheter, subjects were administered a single intravenous dose of 
methadone HCl (2.0 mg, 1.8 mg free base). Venous blood samples were collected over 
the next 72 hours from day 1 to day 4 according to the following schedule: 1, 2, 4, 8, 12, 
24, 48, and 72 hours after the dose. Plasma samples were immediately separated and 
stored at – 80 °C for later analysis. Continuous urine samples were collected over the first 
12 hours after the methadone dose, and stored at – 80 °C. Subject received a standard 
breakfast 2 hours after methadone and free access to food thereafter. (2) Letrozole-treated 
period: on study day 8, subjects began taking a daily oral dose of letrozole (2.5 mg/day) 
each morning at the same time, and continuing through study day 18. Before study day 
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15, subjects were instructed to fast overnight again. On study day 15, the same 
procedures as that on day 1 of the control period involving a single intravenous dose of 
methadone, pre- and post-dosing blood and urine pharmacokinetic sampling were 
repeated from day 15 to day 18. In order to assess patient compliance with daily letrozole 
dosing, the blood drawn immediately before the dose of methadone on study day 15 was 
used to measure plasma letrozole concentrations. Plasma methadone concentrations were 
also measured in these samples to ensure that no methadone remained in the blood before 
the second pharmacokinetic investigation done in the letrozole-treated period. More 
detailed clinical procedures are described in “Chapter Ten: General Methods / Protocol 
for clinical trial: effects of aromatase inhibition on methadone disposition”. 
 
Sample analysis  
HPLC with tandem mass spectrometry detection (LC-MS/MS) assays were 
developed for the quantification of plasma and urinary methadone and its major 
metabolites, EDDP and EMDP. All samples were analyzed as described in “Chapter Ten: 
General Methods / LC-MS/MS assays for plasma and urinary methadone, EDDP and 
EMDP”. Plasma letrozole concentrations were measured using HPLC assays with 
ultraviolet and fluorescence detection as described in “Chapter Ten: General Methods / 
HPLC-UV-fluorescence assays for plasma letrozole”. 
 
Pharmacokinetic analysis 
Data on methadone and its metabolites including area under the concentration-
time curve (AUC), half-life (t½), clearance (CL) and volume of distribution (Vd) were 
47 
 
estimated using a two-compartment model (Phoenix™ WinNonlin® 6.1, Pharsight 
Corporation, Cary, NC). Systemic clearance of intravenous methadone was CLIV = dose / 
AUC0-∞, t½ estimated based on the terminal elimination rate constant, volume of 
distribution based on the terminal phase was Vd = CLIV · t½ / 0.693, and apparent 0 - 12 h 
renal clearance of methadone and its primary metabolite EDDP was estimated as CLr, 0-12h 
= total amount excreted in urine during the first 12 hours / the corresponding AUC0-12 h.  
Note: Equations are quoted from (Rowland and Tozer 1995). 
 
Statistical analysis 
Differences between control and letrozole treatment periods for pharmacokinetic 
parameters including methadone AUC, t½, CLIV, and the ratios of methadone to EDDP 
both in plasma and in urine were analyzed by two-tailed paired t-test (Microsoft Office 
Excel 2007). Statistical significance was assigned at p < 0.05. Relationships between 
pharmacokinetic changes were evaluated by linear regression analysis. 
 
Note: The work described in this chapter has been submitted for publication (Lu, Thong, 
and Flockhart 2011).   
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CHAPTER FOUR 
Screening Select Xenobiotics for Aromatase Inhibition 
 
Introduction  
Studies presented in the last two chapters indicate that aromatase is able to 
metabolize methadone, suggesting that aromatase is not only involved in steroidogenesis, 
but is also a drug-metabolizing enzyme with potential important roles in drug disposition 
and drug interactions. Based on these findings, it is possible that aromatase interacts with 
a broad range of xenobiotic medication. These interactions may in turn affect aromatase 
activity.  
Important drug-metabolizing CYPs, such as CYP1A1, CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A, have been extensively 
studied for their involvements in drug interactions, and the knowledge resulted from 
these studies provides useful guidance for clinical prescription. In contrast, aromatase is 
much less studied. To date, due to the lack of understanding of its role in drug 
metabolism, the possibility of altered clinical drug disposition and the resultant adverse 
drug reaction via aromatase inhibition has not been widely considered. This 
understanding is important not only in the prediction and prevention of pharmacokinetic 
drug-drug interactions, but more so in the treatment of a critical disease that causes high 
fatality and heavy healthcare burden worldwide: breast cancer. The peripheral conversion 
of testosterone to estradiol by aromatase is the primary source of endogenous estrogen in 
post-menopausal women, and the inhibition of aromatase represents a key approach to 
the treatment of hormone-receptor positive breast cancer. The aromatase inhibitor class of 
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drugs is widely used and effective for this indication, but their use is compromised by 
side effects that result in non-compliance and poor quality of life of breast cancer 
patients. It follows that it is important to develop more tolerable aromatase inhibitors with 
improved therapeutic index. At present, most post-menopausal women at high risk are 
treated either with tamoxifen or raloxifene, both of which are indicated in the prevention 
of breast cancer (Chlebowski et al. 1999). However, it has recently become clear that 
many patients eligible for preventive therapy with tamoxifen either refuse to take it, or 
are non-adherent (McCowan et al. 2008). Aromatase inhibitors are also under study for 
this indication and a recent report showed that therapy with one of the available AIs, 
exemestane, was associated with a 65% relative reduction in the annual incidence of 
invasive breast cancer in postmenopausal women who were at moderately increased risk 
for breast cancer (Goss et al. 2011). Unfortunately, musculoskeletal pain compromises 
adherence to therapy with available aromatase inhibitors (Henry et al. 2008). Alternative 
aromatase inhibitors may allow greater compliance by bringing about fewer of the side 
effects. It is possible that novel aromatase inhibitors that allow greater compliance may 
therefore be of value in the prevention setting. For these reasons, and as a first step in 
obtaining better understanding of drug interactions with aromatase, I set out to study the 
effects of xenobiotics on aromatase activity. 
Since my prior work has showed that aromatase is able to metabolize methadone 
(Chapters Two and Three, this dissertation), I hypothesized that this enzyme may interact 
with a small group of drugs and/or their metabolites that I have selected based on the 
following criteria: 1) drugs that are cleared by metabolism via N- or O-demethylation, 
which are metabolic reactions similar to those that aromatase can carry out; 2) drugs that 
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are commonly prescribed to patients with breast cancer. Since understanding interactions 
between aromatase and xenobiotics may be important for the prediction and prevention of 
adverse drug interactions associated with the use of aromatase inhibitors, and since there 
is a need for developing more tolerable aromatase inhibitors with improved therapeutic 
window, I studied these selected xenobiotics for their ability to inhibit aromatase. 
 
Results and discussion 
Using carefully recorded medication data from trials of tamoxifen (Jin et al. 2005) 
and aromatase inhibitor (Henry et al. 2008) conducted by Dr. Flockhart and his 
collaborators in the Indiana University Cancer Center, we determined that selective 
estrogen receptor modulators (SERMs), antidepressants, non-steroidal anti-inflammatory 
drugs (NSAIDs) and opiates for pain control are commonly co-prescribed drugs. Drugs 
that satisfy both criteria include the SERMs, toremifene (Berthou et al. 1994) and 
tamoxifen (Desta et al. 2004); antidepressants, fluoxetine (Liu et al. 2001) and 
venlafaxine (Eap et al. 2003); the NSAIDs, naproxen (Miners et al. 1996) and ibuprofen 
(Hamman, Thompson, and Hall 1997); and the opiates, codeine (Yue et al. 1997), 
tramadol (Paar et al. 1997) and methadone (Sullivan and Due 1973; Chapters Two and 
Three, this dissertation). In addition, there are existing interests in understanding the 
effects of natural compounds that cause endocrine disruption by changing aromatase 
activity (Cheshenko et al. 2008; Sanderson 2006). Since the most clearly characterized 
and clinically important interaction between natural compounds and the cytochrome P450 
system so far is the reduction of CYP3A activity brought about by grapefruit juice 
(Guengerich and Kim 1990), it seems important to understand the effects of grapefruit 
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juice components on aromatase activity. Naringenin is an active component within 
grapefruit juice and therefore was also included in the selected compounds to be tested 
for their ability to inhibit aromatase.  
Each selected compound was tested using a fluorescent aromatase activity assay 
with microsomal incubations. Two of the current aromatase inhibitors: letrozole, a 
competitive inhibitor, and exemestane, a mechanism-based inhibitor, were used as 
positive controls. Since an important exemestane metabolite, 17-hydroxy exemestane, 
may contribute to the clinical effect of exemestane via a similar mechanism, its ability to 
inhibit aromatase was also tested in addition to the select group of compounds. The 
screening results are shown in Figure 4.1.  
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Figure 4.1. Screening selected compounds for their ability to inhibit aromatase. Data 
represent duplicate incubations for each tested compound. (A) The concentration of each 
tested inhibitor was 10 µM. Letrozole at 10 nM was used as a positive control. (B) The 
concentration of tested inhibitor was 10 µM, except that fluoxetine was tested at both 10 
and 20 µM. Letrozole at 20 nM was used as a positive control. (C) The concentration of 
tested inhibitor was 10 µM, except that naringenin was tested at 20 µM. The mechanism-
based inhibitor exemestane at 10 µM was used as a positive control. 
 
The effects of tested inhibitor on aromatase activity were measured with inhibitor 
concentrations set at 10 or 20 µM, and were presented as percent enzyme activity 
remaining compared to vehicle controls. Data showed that methadone metabolite EMDP, 
tamoxifen metabolites N-desmethyl-tamoxifen (NDMT) and endoxifen, fluoxetine, 
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naringenin and 17-hydroxy-exemestane were able to reduce aromatase activity at the 
concentration tested, while methadone and its metabolite EDDP, venlafaxine, ibuprofen, 
tamoxifen and its metabolite 4-hydroxy-tamoxifen, naproxen, toremifene, tramadol and 
codeine did not inhibit aromatase at the concentration of 10 µM.  
In order to better predict aromatase inhibitory effects of these drugs in breast 
cancer patients who are taking them, and to identify potential aromatase inhibitors within 
the current pharmaceutical armamentarium, I selected a few candidates for further studies 
to characterize their detailed inhibitory mechanisms. (1) Among the compounds that 
appeared to be active aromatase inhibitors, fluoxetine is a relatively weak inhibitor at 10 
and 20 µM, and therefore is not likely to bring about clinically meaningful aromatase 
inhibition via a reversible mechanism. However, whether or not aromatase interacts with 
fluoxetine via demethylation merits further studies. (2) The exemestane metabolite, 17-
hydroxy exemestane, is a steroid analogue like its parent drug exemestane. It is likely that 
17-hydroxy-exemestane inhibits aromatase via mechanism-based inhibition similar to the 
action of exemestane, and so it was not included for further characterization because 
aromatase inhibition is already expected when exemestane is given to patients, and the 
efficacy and toxicity profile of 17-hydroxy-exemestane may be close to that of 
exemestane due to their structure and mechanistic similarity. (3) The methadone 
metabolite EMDP is a secondary metabolite and present at relatively very low 
concentrations in patients taking methadone (Lu, Zhou et al. 2011). Since it only 
inhibited aromatase activity by ~ 25% at 10 µM, it is not likely that EMDP itself has 
substantial inhibitory effect on aromatase in vivo. With that said, since aromatase is able 
to metabolize methadone, it is clear that the enzyme interacts with methadone in humans, 
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and the possibility of either competitive inhibition or irreversible mechanism-based 
inhibition by methadone at a higher concentration cannot be ruled out and merits future 
studies. (4) Naringenin substantially reduced aromatase activity at 20 µM. The 
enantiomers of naringenin, (R)- and (S)-naringenin appeared to have different potency as 
aromatase inhibitors and were selected for further investigation, especially for their 
stereoselectivity on aromatase. (5) Most interestingly, NDMT and endoxifen inhibited 
aromatase activity by ~ 37% and ~ 57% respectively. Tamoxifen is an effective therapy 
in the treatment of breast cancer, but the aromatase inhibitory effects brought about by 
tamoxifen metabolites were not known before. Since these effects may contribute to the 
beneficial effects of tamoxifen in breast cancer patients, the ability of tamoxifen 
metabolites to inhibit aromatase deserve detailed studies.   
In summary, these data demonstrate that several xenobiotics interact with 
aromatase in vitro and this fact suggests potential clinical significance. Methadone and 
tamoxifen are common medications taken by breast cancer patients and these drugs, if 
they exert adequate aromatase inhibition in humans, might have beneficial effects that 
could prevent tumor growth and cancer recurrence. Naringenin is often ingested via fruit 
products such as grapefruit juice and therefore might also be protective for people with 
high breast cancer risk. These findings suggest that methadone, naringenin and tamoxifen 
metabolites are important candidates for further mechanistic studies. Moreover, these 
compounds are all structurally different from the known aromatase inhibitors. They might 
employ different kinetic actions on the target enzyme and/or have simultaneous actions 
on other receptors that result in improved risk/benefit profile as a therapy for breast 
cancer patients. Methadone, naringenin and tamoxifen metabolites require further study 
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to allow us to fully exploit their potential to serve as better aromatase inhibitors.  For this 
reason, studies aimed to address these questions were designed and conducted as 
described in detail in the next three chapters. 
 
Methods 
Fluorescent assay for inhibition of aromatase in vitro 
The activity of aromatase was determined by measuring the conversion rate of a 
fluorometric substrate, 7-methoxy-4-trifluoromethylcoumarin (MFC), to its fluorescent 
metabolite, 7-hydroxytrifluoromethylcoumarin (HFC) as described in “Chapter Ten: 
General Methods / Fluorescent assay for inhibition of aromatase in vitro”. 
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CHAPTER FIVE 
Mechanism-based Inhibition of Aromatase by Methadone 
 
Introduction  
Aromatase is able to metabolize methadone both in vitro and in vivo (Chapters 
Two and Three, this dissertation). However, the effects of methadone itself on aromatase 
have not been carefully studied and the effects of methadone on the metabolism of 
endogenous androgens have not been described or tested for. Although when tested at 10 
µM, methadone did not act as a competitive aromatase inhibitor in vitro (Chapter Four, 
this dissertation), it remains possible that methadone has inhibitory effect on aromatase at 
higher tissue concentrations in humans or act as a mechanism–based inhibitor when it is 
metabolized by aromatase.  
Auto-inhibition of methadone metabolism over time seen in some patients has 
been a concern in methadone use. Auto-inhibition during chronic methadone therapy 
might lead to unanticipated accumulation of methadone in patients with resultant 
potentially lethal consequences. A poor understanding of the effects of methadone on its 
own clearance over time also impedes our ability to dose accurately, to anticipate and 
manage withdrawal in clinical settings. Screening results described in the last chapter 
suggest that at least one methadone metabolite, EMDP, may have inhibitory effect on 
aromatase activity. Since it is clear that aromatase catalyzes metabolism of methadone, 
and since aromatase also interacts with methadone metabolites, it is possible that the 
aggregated effect of these interactions reduces the activity of aromatase in humans. In 
addition, this influence on aromatase activity might be in part responsible for methadone 
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action. Some side effects associated with methadone, such as bone loss, are reminiscent 
of estrogen withdrawal (Senay 1985; Backstrom 1995). It follows that the involvement of 
aromatase inhibition and the subsequent alterations in the downstream signaling 
pathways involving androgens and estrogens may help explain these side effects of 
methadone. Lastly, since there is a potential role of aromatase in the disposition of 
xenobiotic medications, methadone, an aromatase substrate, might have an effect on the 
pharmacokinetics of other exogenous substrates of aromatase. 
For these reasons, and as a first step in obtaining a more complete understanding 
of methadone’s interactions with aromatase, I tested the ability of methadone to inhibit 
aromatase under conditions in which either reversible or mechanism-based inhibition of 
the conversion of testosterone to estradiol by aromatase could be quantified.  
 
Results 
Testosterone metabolism by recombinant aromatase 
To measure the activity of aromatase, the rate of aromatization of testosterone to 
17-β-estradiol was used as a marker of enzyme activity. Aromatase was able to catalyze 
the generation of estradiol from testosterone with a Vmax of 9.1 pmol/min/pmol P450 and 
Km of 4.0 µM (pilot data not shown). Under the same incubation conditions, a 
concentration of testosterone at the Km was chosen to test for reversible, competitive 
inhibition of aromatase by methadone. At 50 µM testosterone, the rate of estradiol 
formation was at Vmax. This concentration was therefore chosen for experiments to test 
the mechanism-based inhibition of aromatase by methadone. The rate of estradiol 
formation was used as a measure of CYP activity. 
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No reversible inhibition of aromatase by methadone  
To test for reversible inhibition, racemic methadone was incubated for 30 min 
with testosterone at the Km (4 µM). Figure 5.1 shows the rate of estradiol formation from 
4 µM testosterone in the presence of a range of methadone concentrations from 0 to 2 
mM. No direct effect of methadone on the rate of metabolism of this probe for aromatase 
was observed under these conditions, even at the highest concentration of methadone 
used. The selective aromatase inhibitor letrozole (1 µM) used as positive control, on the 
other hand, was able was to completely block the formation of estradiol.  
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Figure 5.1. Methadone is not a reversible inhibitor of recombinant human 
aromatase.   
Testosterone (4 µM) was incubated with a range of racemic methadone concentrations 
and recombinant human aromatase for 10 min, and aromatase activity was determined by 
measuring the generation of estradiol from testosterone in three experiments. Bars 
represent the average rate of estradiol formation in duplicate samples at increasing 
concentrations of methadone or in the presence of 1µM letrozole (positive control). The 
dotted line indicates the average rate obtained in the absence of methadone.  
 
Mechanism-based inhibition of aromatase by methadone 
Since methadone metabolism to EDDP could be catalyzed by aromatase, pilot 
experiments were conducted to test the ability of methadone to inactivate aromatase 
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activity in a time dependent manner. When aromatase was pre-incubated in the presence 
of 1 mM methadone and then incubated with a Vmax concentration of testosterone (50 
µM), a log linear time-dependent loss of aromatase activity occurred (pilot data not 
shown). If enzyme was pre-incubated under the same conditions without methadone, no 
decrease in enzyme activity was observed and the Vmax activity of estradiol formation 
was maintained. This inactivation was also dependent on methadone concentration. When 
0 - 500 µM racemic methadone was pre-incubated for 25 min, inhibition of 50% of 
activity was seen at approximately 50 µM methadone, while 30% inhibition was brought 
about by the presence of 10 µM methadone (pilot data not shown). When the individual 
enantiomers (0 - 500 µM, over 5 - 20 min) were separately tested under the same 
conditions, no stereoselectivity was observed (data not shown). 
To estimate the kinetics of the interaction between methadone and aromatase 
during preincubation, a range of methadone concentrations and preincubation times were 
tested. Figure 5.2.A depicts the preincubation time and concentration dependence of the 
effect of methadone on aromatase activity. Control incubations were carried out in the 
presence of NADPH but without methadone. The rates of metabolism at zero 
preincubation time for each concentration were consistent with the Vmax activity of 
aromatase under these conditions. It was therefore possible to normalize the data at each 
concentration to the activity seen at 0 min of preincubation. Kinetic analyses of the rates 
of enzyme inactivation in the presence of methadone were carried out using 
NONMEM®, and predicted time curves for inactivation at each methadone concentration 
were obtained (Figure 5.2.A). The KI, and kinact values were calculated to be 40.6 ± 
2.8µM, and 0.061 ± 0.001min-1 respectively. A close correlation between observed and 
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predicted rates of aromatase was observed (Figure 5.2.B), indicating that the data are 
reliably represented by the model. 
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Figure 5.2. Kinetic analysis of mechanism-based inhibition of aromatase by racemic 
methadone.   
 (A) Time- and concentration-dependent inactivation. Methadone (MTD 10, 50, 100, 200, 
500 µM) was pre-incubated with human recombinant aromatase (0.1 µM) for 0, 5, 10, 15, 
or 20 min, and then activity of aromatase (0.01 µM) was assessed in incubations carried 
out in duplicate (n = 2). Individual data points (grey dot) were plotted as the percent of 
aromatase activity observed at 0 min of preincubation. The curve of each plot represents 
the line of best fit for the inactivation reaction at the concentration indicated using 
NONMEM®. (B) Correlation between observed and NONMEM® predicted values of 
percent aromatase activity remaining. The solid line represents the line of equality. A 
correlation coefficient (R2) of 0.99 was obtained.  
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Since methadone is metabolized by aromatase, I tested the possibility that 
inhibition of aromatase by methadone might be due to the metabolites formed. We 
directly tested its major metabolite, EDDP, in both reversible and irreversible 
experimental designs in the same way as described for methadone itself. Similar to the 
results for methadone, no competitive inhibition was observed when EDDP were tested at 
concentrations up to 100 µM (data not shown). When irreversible inhibition was tested, 
inactivation of aromatase was observed by both the primary metabolite, EDDP, and the 
secondary metabolite, EMDP, at concentrations as low as 10 µM (pilot data not shown). 
Figure 5.3 shows that the rate of inactivation by EDDP (100 µM) appeared equipotent as 
that by racemic methadone (100 µM), and the rate of inactivation by EMDP (100 µM) 
was relatively slower. 
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Figure 5.3. Mechanism-based inhibition of aromatase by racemic methadone, EDDP 
and EMDP. 
Methadone, EDDP and EMDP (100 µM) were pre-incubated with recombinant human 
aromatase (0.1 µM) for 0, 5, 10, 15, or 20 min, and then activity of aromatase (0.01 µM) 
was assessed in incubations carried out in duplicate (n = 2). Representative data were 
plotted as the value of log10 (% aromatase activity observed), when normalized to control 
at 0 min of preincubation. 
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Discussion   
Our data show that methadone is able to bring about time- and concentration-
dependent inhibition of aromatase. Since a 10-fold dilution after preincubation of 
aromatase with methadone could not recover the loss of aromatase activity during the 
subsequent incubation of aromatase with testosterone, and since our data also show that 
methadone does not inhibit aromatase in a competitive setting (Figure 5.2), the time- and 
concentration-dependent inhibition of aromatase by methadone we observed is consistent 
with the action of an irreversible inhibitor. Since methadone is also metabolized by 
aromatase (Chapters Two and Three, this dissertation), our data meet established criteria 
(Silverman 1988) for the involvement of methadone as a mechanism-based or “suicide” 
inhibitor of aromatase. Such inhibitory activity is dependent on the catalytic mechanism 
and activity of the enzyme itself, which must first bind the drug and then catalytically 
activate it (Jones et al. 1999). The activated moiety irreversibly alters the enzyme and 
removes it permanently from the pool of active enzyme.  
Because methadone can be metabolized by aromatase, it is possible that during 
preincubation, a portion of methadone is metabolized to its downstream metabolites by 
aromatase. My prior work has shown that the Km value of the conversion of methadone to 
EDDP by aromatase in our recombinant system in vitro is relatively high (314 µM, 
Chapter Two, this dissertation) and the amount of EDDP formation would be very low 
given the preincubation conditions. Since my data also show that the primary metabolite 
EDDP does not have reversible inhibitory activity on aromatase at concentrations up to 
100 µM, and secondary metabolite EMDP only inhibited aromatase activity by ~ 25% at 
10 µM (Chapter Four Figure 4.1.A), it is unlikely that the decreased aromatase activity 
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during incubation with testosterone was due to inhibition by the methadone metabolites 
formed via a reversible mechanism. However, it is possible that EDDP and EMDP 
generated from methadone can inhibit aromatase via an irreversible mechanism during 
preincubation and therefore contribute to the decreased aromatase activity observed when 
methadone was tested. In fact, when EDDP and EMDP were separately tested for their 
ability to irreversibly inhibit aromatase, both metabolites showed time-dependent 
inactivation of aromatase (Figure 5.3). With that said, the potency of these metabolites 
are similar to or lower than that for methadone, and the concentrations of these 
metabolites present in preincubation mixture should be much lower than methadone 
concentrations. As a result, the contribution of methadone metabolism to the observed 
inactivation of aromatase would be minimal.  
Our data indicate that methadone appeared to be a mechanism-based inhibitor of 
aromatase with an inactivation constant KI of ~ 40 µM. Mechanism-based inhibition can 
result from bioactivation of a reactive intermediate that interacts with the heme prosthetic 
group of a cytochrome P450, or that covalently modifies the apoprotein (Hollenberg, 
Kent, and Bumpus 2008; Kalgutkar, Obach, and Maurer 2007), and can involve the 
subsequent formation of a metabolite intermediate complex that inactivates the enzyme 
and takes it out of the active pool (Jones et al. 1999). Such inhibition brought about by 
the formation of a metabolite intermediate complex has been demonstrated for a number 
of N-demethylated drugs including diltiazem (Jones et al. 1999) and erythromycin (Ortiz 
de Montellano et al. 1981). Although my work presented here does not address the 
detailed biochemical interactions underlying the mechanism-based inhibition of 
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aromatase by methadone, it is clear that methadone can irreversibly inactivate aromatase 
in vitro. 
This irreversible inhibition by methadone might be important. Compared to 
reversible inhibition, irreversible inhibition more frequently results in unfavorable drug-
drug interactions as the inactivated P450 enzyme has to be replaced by newly synthesized 
protein (Kalgutkar, Obach, and Maurer 2007), and severe clinical consequences may 
result (Wilkinson 2005). However, the clinical relevance of our data is difficult to 
extrapolate from in vitro data for the following reasons: The concentration of aromatase 
used in our experiments was relatively high. A Km of 4 µM for the conversion of 
testosterone to estradiol was observed when 0.01 µM recombinant aromatase was used, 
while the Km previously reported for this reaction in human placental microsomes was 
0.2 µM (Zharikova et al. 2006). Furthermore, the KI (40 µM) observed here was obtained 
with an aromatase concentration of 0.1 µM, even ten times higher than that mentioned 
above. This relatively high enzyme concentration for preincubation was a limit of our 
studies, but it was chosen to insure accurate quantification of estrogen generation in the 
diluted incubation mixture. Therefore, although the observed KI was higher than the 
plasma concentrations of methadone seen in patients, it may be anticipated that a lower 
KI would be obtained if methadone acts as a mechanism-based inhibitor in the human 
placenta or other tissues due to the lower enzyme concentrations likely to be present in 
tissues in vivo. In addition, while (R)-methadone therapeutic concentrations observed in 
plasma at steady state are in the 0.5 - 1 µM range (Eap, Buclin, and Baumann 2002), the 
concentration of this highly hydrophobic drug in tissues and at the aromatase active site 
may be substantially higher (Levine et al. 1995). It remains possible that methadone 
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reduces local aromatase activity in human tissues where aromatase concentration is much 
lower than that was used in our studies. Thus, future investigation is required in order to 
address whether or not methadone inhibits aromatase in vivo. 
In addition, EDDP appeared to be as potent an irreversible inhibitor of aromatase 
as methadone itself, while EMDP appeared weaker, suggesting that methadone 
metabolites might be able to inhibit aromatase in vivo. However, this is not likely in 
patients taking methadone because these metabolites are present at much lower 
concentrations than methadone (Lu, Zhou et al. 2011; Kharasch et al. 2008). Of note, the 
conversion of EDDP to EMDP is a demethylation reaction. Whether or not aromatase is 
able to carry out this reaction has not been tested, but this possibility remains. 
A few clinical observations are consistent with inhibition of aromatase by 
methadone. Deceased aromatase activity leads to altered metabolism and disposition of 
endogenous testosterone and androstenedione. Lower concentrations of estradiol and of 
follicle-stimulating hormone have been documented in men taking methadone (Hallinan 
et al. 2009), and low bone mineral density that may be due to low estrogen concentrations 
has been documented in 83% of patients in a methadone maintenance treatment program 
(Kim et al. 2006). Conceivably, other side effects of methadone that include flushing, 
muscle pain and symptoms consistent with estrogen withdrawal (Senay 1985; Backstrom 
1995) may be explained in part by the drug’s action on aromatase. In addition, 
unexpected methadone accumulation over time occurs in some patients, and multiple 
factors may underlie the variability observed in methadone pharmacokinetics including 
auto-inhibition (Morton 2007). The inhibitory effects of methadone on its own 
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metabolism by aromatase may be a contributor to the auto-inhibition of methadone 
clearance. 
Overall, these studies have shown that methadone and its metabolites are 
irreversible inhibitors of aromatase in vitro. Since methadone itself is metabolized by 
aromatase, these interactions improve our understanding of possible mechanisms 
underlying variability in methadone clearance. While the clinical relevance of the 
inhibition of aromatase by methadone or its metabolites is not clear, the ability of these 
compounds to inhibit aromatase improves our understanding of aromatase. The 
irreversible mechanisms employed by these compounds could be further exploited for 
new ways to regulate aromatase activity for therapeutic purposes. 
 
Methods 
Testosterone metabolism in vitro by recombinant aromatase 
All incubations were carried out under the incubation conditions described in 
“Chapter Ten: General Methods / Testosterone and methadone metabolism in vitro by 
recombinant aromatase”. 
  
Quantification of estradiol formation 
High performance liquid chromatography (HPLC) assays with ultraviolet (UV) 
detection were developed for the quantification of testosterone conversion to estradiol as 
described in “Chapter Ten: General Methods / HPLC-UV assays for the quantifications 
of estradiol and EDDP formation”.  
 
71 
 
Reversible inhibition of recombinant aromatase 
Solutions of testosterone and tested inhibitor were mixed, and methanol was 
removed by drying in speed vacuum before the incubation. Incubations were then carried 
out in the same way as described in “Chapter Ten: General Methods / Testosterone and 
methadone metabolism in vitro by recombinant aromatase” except that the final 
testosterone and aromatase concentrations were 4 µM and 0.01µM, respectively. The 
inhibition of aromatase by methadone or letrozole was determined by measuring the 
conversion rate of testosterone to estradiol.  
 
Mechanism-based inhibition of recombinant aromatase 
Irreversible inhibition of recombinant aromatase was tested by preincubating 
aromatase with various concentrations of tested inhibitor as described in “Chapter Ten: 
General Methods / Mechanism-based inhibition of aromatase in vitro”. The extent of 
inactivation of aromatase was determined by measuring the conversion rate of 
testosterone to estradiol during incubation. 
 
Kinetic analyses 
Formation rates of estradiol at different testosterone concentrations were fit to one 
site Michaelis-Menten kinetic models using Prism version 5.01 for Windows (GraphPad 
Software Inc., San Diego, CA). 
The rates of metabolite formation from substrate probes in the presence of the test 
inhibitors were compared with those for control in which the inhibitor was replaced with 
vehicle. The inhibition data were fit to different models of enzyme inhibition 
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(competitive, non-competitive, and uncompetitive). The equations for kinetic and 
inhibition analyses of the data were constructed using NONMEM V v1.1 ® (ICON, 
Hanover MD and UCSF), utilizing the nonlinear regression functionality. The 
appropriateness of the fit was determined by visual inspection and by using the objective 
function, residual patterns, residual sums of squares, and precision of the parameter 
estimates. The correlation coefficient and its corresponding statistical significance were 
determined by conventional methods. 
 
Determination of kinact and KI 
KI and kinact values were estimated using an approach that involves a simultaneous 
fit of all the data. Data from experiments documenting the time course of inactivation 
were used for the calculation of inhibition kinetic parameters. Estradiol formation was 
expressed as pmol/min/pmol aromatase and the percentage of remaining activity was 
calculated as shown in the following equation: 
 
where Et is the enzyme activity expressed as estradiol  formation at time t, and E0 is the 
average estradiol formation at preincubation time zero (100%). The extent of inhibition 
was expressed as: 1 – % of remaining enzyme activity. 
The pseudo first-order rate constant for enzyme inactivation, λ, was estimated 
from the aggregation of all the data using equation:  
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The relationship between λ and inhibitor concentration was fit to the following equation: 
 
where kinact is the rate constant for inactivation, [I] is inhibitor or inactivator 
concentration, and KI is the inactivator concentration that produced half the maximal rate 
of inactivation, analogous to a Km. This equation assumes there was negligible change of 
[I] during the incubation period and that loss of enzyme was due to inactivation. As 
indicated above, all the data were fitted for each inhibitor concentration to obtain a single 
estimate for kinact and a single estimate for KI using these equations.  
Note: Equations are quoted from (Jones et al. 1999). 
 
Note: The work described in this chapter has been published (Lu et al. 2010). 
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CHAPTER SIX 
Stereoselective Inhibition of Aromatase by Naringenin 
 
Introduction 
There is existing interest in the effects of dietary factors on the cytochrome P450 
system in order to better understand food-drug interactions. Interactions between food 
and aromatase (CYP19) are also of interest due to potential influence on estrogen 
synthesis. Xenoestrogens are industrial or dietary compounds that can affect 
steroidogenesis and cause endocrine disruption by changing aromatase activity. Our 
preliminary results (Chapter Four, this dissertation) suggest that naringenin may be one 
of these xenoestrogens that can inhibit aromatase in vivo. Naringenin (Figure 6.1, 
Structure 1) is a chiral flavanone belonging to the flavonoid class. It is contained in some 
citrus species, in particular grapefruit, that contain large amounts of its 7-O-
neohesperidoside, naringin (Figure 6.1, Structure 2). Upon ingestion, naringin undergoes 
cleavage of the sugar moiety, leaving the free aglycone, naringenin in the gastrointestinal 
tract (Yanez and Davies 2005). Naringenin is known to reduce CYP3A activity in 
humans, but its effects on aromatase has not been carefully studied. My prior screening 
results (Chapter Four, this dissertation) indicate that naringenin substantially reduced 
aromatase activity at 20 µM and the enantiomers of naringenin, (R)- and (S)-naringenin, 
appeared to have different potency as aromatase inhibitors. These data suggest that fruit 
products containing naringenin might affect aromatase activity in vivo. 
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Figure 6.1. Structures of naringenin and naringin. 
Compound structure represents naringenin when R = H (1) or naringin when R = 
neohesperidosyl (2). Source: modified from structure figures provided by our 
collaborator Dr. Salvatore Caccamese at Università di Catania, Catania, Italy. 
 
The inhibition of CYP enzymes by flavonoids like naringenin may be of medical 
importance. Since the demonstration that grapefruit juice can inhibit the metabolism of 
the CYP3A substrate felodipine (Bailey et al. 1993), it has become widely appreciated 
that the ingestion of a number of fruit juices can slow drug metabolism (Bailey et al. 
2004), and thereby increase the concentrations of important medications such as 
cyclosporine (Lee et al. 2001) and methadone (Benmebarek et al. 2004). The biochemical 
basis for these interactions involves the interaction of flavonoids with specific CYP 
isoforms. In order to be aware of any potential clinically relevant interactions between 
naringenin and both endogenous and exogenous substrates of aromatase, it is therefore 
important to study interactions of naringenin with aromatase.  
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Naringenin has been reported to have a number of potential health related 
properties. In a previous study, naringenin was found to inhibit the CYP3A4-mediated 
oxidation of two dihydropyridine cardiodepressive drugs, more markedly than naringin 
(Guengerich and Kim 1990). Later, naringenin was found inter alia to inhibit the activity 
of CYP isoforms that activate the potent environmental carcinogen, nicotine-derived 
nitrosamine ketone (Bear and Teel 2000). Naringenin also inhibited quinine 3-
hydroxylation mediated by CYP3A4 (Ho, Saville, and Wanwimolruk 2001). It may also 
act as a potent immunomodulator in mice with pulmonary fibrosis (Du et al. 2009), and 
the antioxidant properties of naringenin and other polyphenols have been well studied 
(Manthey, Grohmann, and Guthrie 2001). 
Despite a volume of research over many years, the relevance of stereochemistry at 
the C-2 stereogenic centre of naringenin has not been carefully evaluated. It is well 
known that interactions between an enzyme system and a substrate are frequently 
stereospecific (Crossley 1992), and often influence the potency of, and the response to a 
single enantiomer (Hutt 2006). For example, quinidine is a clinically relevant and potent 
inhibitor of CYP2D6, while its diastereomer quinine is not (Muralidharan et al. 1991), 
(S)-lansoprazole is a more potent inhibitor of CYP2C9, CYP2C19, CYP2D6, CYP2E1 
and CYP3A4-mediated hydroxylation than (R)-lansoprazole (Liu et al. 2005) and many 
other chiral drugs have been well documented to exhibit enantioselective inhibition of 
P450-mediated metabolism (Carabaza et al. 1997; Shin, Kane, and Flockhart 2001; 
Dilmaghanian et al. 2004). Difficulties in separating enantiomers and the resulting 
absence of readily available pure enantiomers have limited research in this area until 
now.  
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In this study, we obtained purified (R)- and (S)- naringenin preparations together 
with the racemate, rac-naringenin, and tested for their ability to inhibit aromatase, with a 
focus on the enantioselectivity of the interaction. In addition, in order to obtain a better 
understanding of naringenin action on the CYP system, the effects of the (R)-, (S)- and 
rac-naringenin on other important human drug-metabolizing CYP isoforms, including 
CYP2B6, 2C9, 2C19, 2D6 and 3A, and their corresponding enantioselectivity were also 
tested. 
 
Results 
Dose-dependent inhibition of recombinant human aromatase by naringenin was 
demonstrated (Figure 6.2). When the enantiomers of naringenin were tested, 
stereoselective inhibition was shown. Specifically, the (S)-naringenin inhibited aromatase 
with an IC50 value of 1.4 (1.1, 1.7) µM, and was approximately 2-fold more potent than 
the (R)-naringenin, which had an IC50 value of 2.8 (2.4, 3.4) µM. The IC50 value for rac-
naringenin was 2.0 (1.7, 2.4) µM, between that for the (R)-enantiomer and that for the 
(S)-enantiomer (Figure 6.2).  
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Figure 6.2. Enantioselective inhibition of human aromatase by naringenin.  
A range of concentrations of rac-naringenin (open circle), (R)-naringenin (dark square), 
or (S)-naringenin (dark triangle) was incubated with recombinant human aromatase (7.5 
nM) and substrate MFC at 37 °C for 30 min and enzyme activity was determined in three 
independent experiments. Individual points represent the mean of duplicate incubations.  
 
Naringenin was also tested for its ability to inhibit a number of other important 
drug-metabolizing CYP isoforms. Data indicate that naringenin inhibited CYP2C9, 
CYP2C19, and CYP3A in an enantioselective way (Figures 6.3 - 6.5). While the (S)-
enantiomer was approximately 2-fold more potent than the (R)-enantiomer as an inhibitor 
of CYP2C19, the (R)-enantiomer was about 2-fold more potent as an inhibitor of 
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CYP2C9 and CYP3A (Table 6.1). In each case, the IC50 value for rac-naringenin was 
between that for the (R)-enantiomer and that for the (S)-enantiomer. No appreciable 
inhibition of CYP2B6 or CYP2D6 was observed at concentrations up to 10 µM (data not 
shown).  
Note: Experiments using human liver CYP3A were performed by my colleague Cong Xu 
in the Department of Pharmacology and Toxicology here at Indiana University. 
 
 
Figure 6.3. Enantioselective inhibition of human CYP2C9 by naringenin.  
A range of concentrations of rac-naringenin (open circle), (R)-naringenin (dark square), 
or (S)-naringenin (dark triangle) was incubated with recombinant human CYP2C9 (15 
nM) and substrate MFC at 37 °C for 45 min and enzyme activity was determined in three 
independent experiments. Individual points represent the mean of duplicate incubations.   
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Figure 6.4. Enantioselective inhibition of human CYP2C19 by naringenin.  
A range of concentrations of rac-naringenin (open circle), (R)-naringenin (dark square), 
or (S)-naringenin (dark triangle) was incubated with recombinant human CYP2C19 (7.5 
nM) and substrate CEC at 37 °C for 30 min and enzyme activity was determined in three 
independent experiments. Individual points represent the mean of duplicate incubations.  
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Figure 6.5. Enantioselective inhibition of human CYP3A by naringenin.  
A range of concentrations of rac-naringenin (open circle), (R)-naringenin (dark square), 
or (S)-naringenin (dark triangle) was incubated with pooled human liver microsomes 
(protein concentration 0.25 mg/ml) and probe substrate testosterone at 37 °C for 15 min 
and enzyme activity was determined in two independent experiments. Individual points 
represent the mean of duplicate incubations. Source: These experiments using human 
liver CYP3A were performed by my colleague Cong Xu. The study design and data 
analysis were carried out by me.  
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Table 6.1. IC50 values for enantioselective inhibition of multiple human CYP 
isoforms by naringenin. 
 
Note: IC50 values are expressed as mean (95% confidence interval). Source: Data on 
CYP19, 2C9 and 2C19 were from me, and data on CYP3A were generated in 
collaboration with my colleague Cong Xu. 
 
Discussion 
Many naturally occurring flavonoids and isoflavanoids exist as stereoisometric 
mixtures, in which one enantiomer predominates. These studies demonstrate the ability of 
naringenin to inhibit aromatase and several other CYP isoforms in vitro. Previous studies 
have shown that maximal plasma concentrations of naringenin after ingestion of 
grapefruit juice are ~ 6 µM (Erlund et al. 2001). The IC50 values of naringenin we 
observed all fall in the low micromolar range (Table 6.1). These data suggest that 
naringenin may have effects in vivo on the activity of multiple enzymes, including 
aromatase, CYP2C9, CYP2C19 and CYP3A. Such inhibitory effects might contribute to 
the clinically observed food-drug interactions brought about by grapefruit juice and other 
fruit products (Dresser and Bailey 2003). Our data are consistent with those reported on 
inhibition of CYP3A by grapefruit and other juices in humans (Bailey, Dresser, and Bend 
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2003; Bailey et al. 2004). However, fruit juices contain other components that might also 
inhibit CYP3A in vivo. The quantitative contribution of naringenin to the overall clinical 
effect is currently unclear. Whether or not interactions between naringenin and other 
CYP isoforms, including aromatase, carry similar clinical relevance must await further 
research. 
While a large literature exists on the effects of grapefruit and other juices on 
CYP3A, few attempts have been made to study their effects on other isoforms. Our 
studies have characterized for the first time the different pharmacologic properties of the 
enantiomers of naringenin on multiple enzymes. Studies with purified (R)- and (S)-
naringenin showed that the individual enantiomers had different affinities for every 
enzyme tested, indicating that naringenin is a pleiotropic and stereoselective inhibitor in 
vitro. While this stereoselective inhibition is clear, the potency difference between 
enantiomers was about two fold in every case. Whether or not this stereoselectivity 
represents clinical significance is unknown. Since the predominant enantiomer of 
naringenin in natural fruits is also unknown, the vulnerability of specific enzymes in vivo 
cannot be estimated yet. Nevertheless, our findings identify interactions between specific 
CYP isoform and naringenin that deserve further study in order to more precisely predict 
the potential risks for food-drug interactions. Such future studies are potentially important 
because interactions between naringenin and drugs that are substrates of CYP2C9 such as 
(S)-warfarin (Rettie et al. 1992), of CYP2C19, such as clopidogrel (Kreutz et al. 2010), 
and of aromatase, such as methadone (Chapters Two and Three, this dissertation) may 
exist. 
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Our data also shed light on the stereoselective preferences of specific CYP 
isoforms. Since other chiral flavonoids contained in fruits may also possess similar 
stereoselective pharmacologic and biological effects, this work improves our 
understanding of the susceptibility of individual CYP isoforms to inhibition by dietary 
factors. In particular, inhibition of aromatase by natural products might be therapeutically 
useful for breast cancer patients, and might be protective for people who are at risk. 
Although our in vitro results indicate that naringenin itself is not likely to serve as a 
selective candidate for this purpose because it inhibits several CYPs, the development of 
novel aromatase inhibitors from natural compounds that are more selective still 
represents a potentially important direction for future research. Of note, naringin, the 
natural precursor of naringenin, is present as (2S)- and (2R)-diastereomers in grapefruit, 
sour orange and pummelo with the (2S)-naringin being predominant, and the ratio (2S) / 
(2R) of the concentrations of the diastereomers markedly decreases during maturation 
(Caccamese, Manna, and Scivoli 2003; Caccamese, Bianca, and Santo 2007; Caccamese 
and Chillemi 2010). Since our data show that the inhibitory effect of natural compounds 
such as naringenin on aromatase can be stereoselective, the effects of fruit juices on 
aromatase may be affected by the degree of maturation of the fruits.  
Although the clinical relevance of these findings warrant further research, 
inhibition of aromatase by naringenin observed in vitro may be exploited to understand 
pharmacokinetic changes seen in vivo. The stereoselective properties exhibited by 
naringenin here could provide insight into the use of naringenin and other flavonoids as 
novel, selective therapeutic agents. 
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Methods 
Fluorescent assay for inhibition of aromatase in vitro 
The activity of aromatase was determined by measuring the conversion rate of a 
fluorometric substrate, 7-methoxy-4-trifluoromethylcoumarin (MFC), to its fluorescent 
metabolite, 7-hydroxytrifluoromethylcoumarin (HFC) as described in “Chapter Ten: 
General Methods / Fluorescent assay for inhibition of aromatase in vitro”. 
 
Inhibition of recombinant human CYP isoforms  
The activity of each recombinant human CYP isoform was determined by 
measuring the conversion rate of a fluorometric substrate to its fluorescent metabolite as 
described in “Chapter Ten: General Methods / Inhibition of recombinant human CYP 
isoforms”. 
 
Kinetic analyses 
The rates of metabolite formation from substrate probes in the presence of the test 
inhibitors were compared with those for control in which the inhibitor was replaced with 
vehicle. The extent of CYP inhibition was expressed as percent enzyme activity 
remaining compared to control. IC50 values were determined as the inhibitor 
concentration that brought about a 50% reduction in enzyme activity by fitting all the 
data to a one-site competition equation using Prism version 5.01 for Windows (GraphPad 
Software Inc., San Diego, CA). 
 
Note: The work described in this chapter has been published (Lu, Ferlito et al. 2011). 
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CHAPTER SEVEN 
Competitive and Non-competitive Inhibition of Aromatase by  
Tamoxifen Metabolites 
 
Introduction  
Prior screening results (Chapter Four, this dissertation) indicate that at least two 
tamoxifen metabolites can decrease aromatase activity when tested at 10 µM in vitro. 
Tamoxifen is a selective estrogen receptor modulator also used in the treatment of 
estrogen-sensitive breast cancer. The biochemical mechanism of action of tamoxifen in 
the treatment of breast cancer is widely understood to involve two active metabolites, 4-
hydroxy-N-desmethyl-tamoxifen (endoxifen) and (Z)-4-hydroxy-tamoxifen (4HT). The 
anti-estrogenic effects of tamoxifen were thought to be exclusively mediated via these 
active metabolites that bind to estrogen receptor and thereby modulate estrogen signaling. 
These metabolites are approximately 100 times more potent, relative to the parent drug, 
as antagonists of estrogen binding to the estrogen receptor and as inhibitors of estrogen-
stimulated growth in sensitive breast cancer cell lines (Furr and Jordan 1984; Kisanga et 
al. 2004; Jin et al. 2005). The discovery that the principal active metabolite, endoxifen is 
produced via metabolism from N-desmethyl-tamoxifen (NDMT), by a genetically 
polymorphic enzyme, CYP2D6 (Jin et al. 2005; Stearns et al. 2003), has led many 
clinical investigators to test the possibility that CYP2D6 genotype might be a useful 
biomarker of tamoxifen efficacy. These efforts have produced mixed results (Goetz et al. 
2005; Wegman et al. 2007; Higgins and Stearns 2010). While some investigators have 
shown a association between CYP2D6 poor metabolizer genotype and increased 
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recurrence of breast cancer in some settings (Goetz et al. 2005), other investigators, using 
different trial designs and alternative study approaches have either failed to show any 
association (Nowell et al. 2005), or have shown an association in the opposite direction 
(Wegman et al. 2007). As a result, the clinical utility of a CYP2D6 genotype guided 
approach to predicting response to tamoxifen has not been clearly demonstrated (Higgins 
et al. 2009). The closely related concept that endoxifen or 4HT concentrations in the 
blood might predict the outcome of tamoxifen therapy in individual patients has also not 
been validated in any clinical study. Similarly, predicting which patients are at risk for 
side effects of tamoxifen is also difficult. Many patients experience hot flashes (Mortimer 
et al. 2008; Henry et al. 2009), muscle aches (Fisher et al. 2005) and other symptoms that 
limit their compliance with treatment, and clearly result in increased rates of breast 
cancer recurrence (Thompson et al. 2010). Although it has been suspected that these side 
effects are caused by estrogen receptor antagonism, no relationship between the 
concentrations of the estrogen receptor modulating metabolites of tamoxifen and the 
incidence or severity of side effects has been reported. Furthermore, although CYP2D6 
genotype is clearly associated with the concentrations of these active metabolites (Jin et 
al. 2005), it has not been consistently shown to predict hot flashes experienced by 
patients taking tamoxifen (Goetz et al. 2005; Henry et al. 2009).  
One possible explanation for this lack of association may be the involvement of 
mechanisms discrete from the 2D6-dependent estrogen receptor antagonism. Tamoxifen 
has a complex metabolic profile involving many active and inactive metabolites (Desta et 
al. 2004). The estrogen receptor binding characteristics of a large number of these 
metabolites have been extensively documented in the search for novel SERMs 
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(Katzenellenbogen et al. 2000; Lim et al. 2005). In fact, a key, potent metabolite, 
endoxifen is under active clinical development (Ahmad, Ali et al. 2010; Ahmad, 
Shahabuddin et al. 2010). In contrast, the ability of many tamoxifen metabolites to exert 
anti-estrogenic effects via alternative mechanisms has not been studied. Among 
alternative mechanisms for tamoxifen action, the inhibition of aromatase seems possible 
because the aromatase inhibitor class of drugs bring about hot flashes and 
musculoskeletal pains similar to those experienced by patients taking tamoxifen (Howell 
et al. 2005; Zivian and Salgado 2008). The commonality of these side effects may reflect 
a shared biochemical mechanism. Consistent with a reduction in aromatase activity, 
tamoxifen significantly lowers estrogen in post-menopausal women (Lonning et al. 
1995).  
Tamoxifen and the AI class of drugs are both effective endocrine therapies for 
breast cancer, and they bring about some common side effects, but the effect of 
tamoxifen therapy on aromatase has not been studied until now. Since tamoxifen is 
metabolized via several pathways to various downstream molecules in humans, and since 
anti-estrogenic effects may be brought about not only by estrogen antagonism, but also 
by reduced estrogen synthesis. For these reasons, I hypothesize that the clinical effects of 
tamoxifen may be mediated in part by actions of tamoxifen or its metabolites as 
aromatase inhibitors. To investigate this possibility, I tested the ability of tamoxifen, its 
three major human metabolites and a number of its minor metabolites to inhibit the 
activity of aromatase in vitro.  
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Results 
Non-competitive inhibition of aromatase by endoxifen and NDMT 
Inhibition of aromatase by tamoxifen and its three major metabolites, 4HT, 
NDMT and endoxifen, was separately tested by measuring their effects on the rate of 
generation of a fluorescent metabolite from a fluorometric substrate, MFC, during 
incubation with aromatase. As shown in Figure 7.1, endoxifen and NDMT inhibited 
aromatase with higher potency than tamoxifen or 4HT. When substrate concentration was 
set at 25 µM, endoxifen and NDMT exhibited IC50 values of 6.1 µM and 20.7 µM, 
respectively, while tamoxifen and 4HT were estimated to have IC50s of 986 µM and 531 
µM, respectively (Table 7.1). Under the same conditions, letrozole was used as a positive 
control and had an IC50 of 5.3 nM. When the endogenous substrate of aromatase, 
testosterone, was included as a competing substrate, an IC50 of 0.33 µM was observed. 
 
Table 7.1. IC50 values of inhibitors of recombinant human aromatase.  
 
Note: IC50 values were determined when substrate MFC and aromatase concentrations 
were set at 25 µM and 7.5 nM respectively as describe in the “Methods” section. 
 
  
90 
 
 
Figure 7.1. Inhibition of aromatase by tamoxifen and its metabolites.  
Curves represent percent aromatase activity remaining in the presence of a range of 
concentrations of endoxifen (open circle), tamoxifen (dark triangle), NDMT (dark circle) 
and 4HT (open triangle). Individual points represent the mean of four independent 
incubations. 
 
To further explore the mechanism of the inhibition by endoxifen and NDMT, I 
tested inhibition by these metabolites across a range of fluorometric substrate 
concentrations. The data were plotted as Dixon and Eadie-Hofstee plots (Figures 8.2 and 
8.3). The profile of the lines on the resulting Dixon plots: straight lines intersecting at a 
common point on the x-axis, is consistent with non-competitive inhibition by endoxifen 
and NDMT (Figures 7.2.A and 8.3.A). The parallel relationship of the lines in the Eadie-
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Hofstee plots is consistent with decreasing maximum enzyme activity Vmaxi and 
unchanged substrate equilibrium dissociation constant KSapp as inhibitor concentration 
was increased (Figures 7.2.B and 8.3.B), observations that were also consistent with a 
non-competitive mechanism. The data indicate a Ki for endoxifen of 4.0 µM, and a Ki for 
NDMT of 15.9 µM. 
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Figure 7.2. Non-competitive inhibition of MFC metabolism by endoxifen.  
 (A) Dixon plot of inhibition of aromatase by endoxifen with MFC concentrations set at 
10 (open circle), 15 (dark circle), 20 (open square) and 25 (dark diamond) µM. (B) 
Eadie-Hofstee plot of inhibition of aromatase by endoxifen with increasing inhibitor 
concentrations: 0 (dark triangle), 1.56 (open circle), 3.13 (dark circle), 6.25 (open square) 
and 12.5 (dark diamond) µM. A range of MFC concentrations was incubated with 7.5 nM 
recombinant human aromatase for 30 min in the absence and presence of 1.56, 3.13, 6.25 
or 12.5 µM endoxifen. Individual points represent the mean of duplicate incubations. 
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Figure 7.3. Non-competitive inhibition of MFC metabolism by NDMT. 
(A) Dixon plot of inhibition of aromatase by NDMT with MFC concentrations set at 10 
(open circle), 15 (dark circle), 20 (open square) and 25 (dark diamond) µM. (B) Eadie-
Hofstee plot of inhibition of aromatase by NDMT with increasing inhibitor 
concentrations: 0 (dark triangle), 3.13 (open circle), 6.25 (dark circle), 12.5 (open square) 
and 25 (dark diamond) µM. A range of MFC concentrations was incubated with 7.5 nM 
recombinant human aromatase for 30 min in the absence and presence of 3.13, 6.25, 12.5 
or 25 µM NDMT. Individual points represent the mean of duplicate incubations. 
 
To study the inhibitory mechanism using an alternative approach, the same data 
were plotted using Lineweaver-Burke plots. The data obtained also indicate that both 
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endoxifen and NDMT decreased the apparent Vmax (Vmaxi), while leaving the apparent Km 
(KSapp) unchanged (Table 7.2), once more consistent with non-competitive inhibition. 
 
Table 7.2. Effect of endoxifen and NDMT on KSapp and Vmaxi of recombinant human 
aromatase. 
 
Note: KSapp and Vmaxi values were determined using Lineweaver-Burke plot as described 
in the “Methods” section. 
 
Furthermore, I tested the ability of the metabolites that inhibited MFC metabolism 
by aromatase to inhibit testosterone metabolism to estrogen. In order to confidently detect 
the generation of estrogen, I incubated a higher concentration of aromatase (50 nM) with 
multiple testosterone concentrations chosen to be within the linear range around the Km 
(4 µM). When a range of concentrations of endoxifen were incubated with testosterone 
and aromatase under these conditions, endoxifen inhibited the generation of estrogen with 
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a Ki of 178 µM, with kinetics examined using Dixon and Eadie-Hofstee plots that again 
indicate non-competitive inhibition (Figure 7.4). Equivalent experiments with NDMT 
indicated that NDMT was a weaker inhibitor than endoxifen (data not shown), but 
experiments for Ki determination could not be carried out due to its relative insolubility at 
higher concentrations which were desired. 
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Figure 7.4. Non-competitive inhibition of testosterone metabolism by endoxifen.  
 (A) Dixon plot of inhibition of aromatase by endoxifen with testosterone concentrations 
set at 1 (open circle), 2 (dark circle), 4 (open square) and 8 (dark diamond) µM. (B) 
Eadie-Hofstee plot of inhibition of aromatase by endoxifen with increasing inhibitor 
concentrations: 0 (open triangle), 50 (dark triangle), 100 (open circle), 200 (dark circle), 
400 (open square) and 600 (dark diamond) µM. A range of testosterone concentrations 
was incubated with 50 nM recombinant human aromatase for 10 min in the absence and 
presence of 0, 50, 100, 200, 400 or 600 µM endoxifen. Individual points represent the 
mean of duplicate incubations. 
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In order to further test whether these observations applied in a more 
physiologically relevant system, I tested the ability of tamoxifen, 4HT, endoxifen and 
letrozole to inhibit the conversion of MFC to HFC by human placental aromatase. Under 
the same conditions as used in MFC incubations with recombinant enzyme, and with the 
substrate concentration set at 25 µM, the selective inhibitor letrozole (20 nM) completely 
inhibited aromatase activity. Endoxifen was able to inhibit placental aromatase with an 
IC50 of 5 µM. Consistent with our previous data, NDMT inhibited placental aromatase 
with a weaker potency while tamoxifen and 4HT did not inhibit at concentrations up to 
50 µM (data not shown).  
Since the Ki for endoxifen determined at this higher enzyme concentration (50 
nM) using testosterone as substrate, was notably higher than that obtained at 7.5 nM of 
aromatase using MFC as substrate, I tested whether the experimental conditions used in 
the testosterone incubations, including in particular the increased enzyme concentration 
would result in an increase in the observed IC50 of endoxifen. Under the same conditions 
as those when an enzyme concentration of 50 nM was used, an IC50 of 95 µM for 
endoxifen was observed in inhibition of MFC metabolism (data not shown), which was 
15 to 16 fold higher in comparison to 6.1 nM as shown in Table 7.1.  
When tamoxifen, 4HT, NDMT or endoxifen was pre-incubated with aromatase 
for 5, 10, 15 and 20 min to test the possibility of irreversible inhibition, no decrease in 
MFC metabolism to HFC or testosterone metabolism to estradiol relative to control was 
observed (data not shown). These data suggest that the inhibition of aromatase observed 
with endoxifen and NDMT is a reversible process. 
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Competitive inhibition of aromatase by norendoxifen 
Pilot studies suggested that among a number of minor tamoxifen metabolites, a 
tertiary metabolite, N,N-didesmethyl-4-hydroxytamoxifen, might have the most potent 
inhibitory effects on aromatase activity (Chapter Eight Figure 8.1). Since N,N-
didesmethyl-4-hydroxytamoxifen is the demethylated product from endoxifen, we have 
named it norendoxifen. The effects of norendoxifen on aromatase activity were tested 
across a range of fluorometric substrate concentrations. The data were plotted as Dixon 
and Lineweaver-Burke plots. The lines on the resulting Dixon plot intersecting at a 
common point indicated a Ki of 35 nM (Figure 7.5.A). The profile of the lines on the 
resulting Lineweaver-Burke plot: straight lines intersecting at a common point on the y-
axis was consistent with a competitive mechanism of inhibition by norendoxifen (Figure 
7.5.B). In order to explore the stereoselectivity of norendoxifen, the potency of the 
purified (E)-enantiomer of norendoxifen was tested. Under the same experimental 
conditions, the IC50 values for (E)-norendoxifen and the unseparated mixture were both 
approximately 30 nM (data not shown). No obvious stereoselectivity was observed. 
A number of other minor tamoxifen metabolites were also found to be relatively 
weak aromatase inhibitors in vitro. The activities of these metabolites are described in the 
next chapter. 
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Figure 7.5. Competitive inhibition of aromatase by norendoxifen.  
A range of substrate (MFC) concentrations was incubated with 7.5 nM recombinant 
human aromatase for 30 min in the absence and presence of norendoxifen. (A) Dixon plot 
of inhibition of aromatase by norendoxifen with substrate (MFC) concentrations set at 10 
(open circle), 20 (dark circle), 30 (open square), 50 (dark diamond) and 100 (open 
triangle) µM. (B) Lineweaver-Burke plot of inhibition of aromatase with increasing 
norendoxifen concentrations: 0 (open square), 10 (dark circle), 25 (open circle), 50 (dark 
diamond) and 100 (open triangle) nM. Individual points represent the mean of duplicate 
incubations. 
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In order to test whether the inhibitory effect of norendoxifen on aromatase 
extends to other CYP enzymes, the ability of this compound to inhibit other important 
drug-metabolizing CYP enzymes was tested, including CYP2B6, CYP2C9, CYP2C19, 
CYP2D6 and CYP3A. When CYP2B6 and CYP2D6 were tested, no substantial 
inhibition by norendoxifen was observed at concentrations up to 1 µM. Three 
experimental systems were used to test inhibition of aromatase, CYP2C9, CYP2C19 and 
CYP3A by norendoxifen: drug incubations with recombinant CYP isoforms, pooled 
placental microsomes or pooled human liver microsomes. Initially, when recombinant 
CYP isoforms were used, norendoxifen inhibited aromatase, CYP2C9 and CYP2C19 
with IC50 values of 30, 95 and 61 nM respectively. These data did not suggest obvious 
CYP isoform selectivity. Since the enzyme concentrations and configurations present in 
recombinant systems may not represent the dynamic multi-enzyme system present in 
vivo, CYP3A was not tested in this system. Instead, the selectivity of norendoxifen was 
further characterized using pooled placental and pooled human liver microsomes under 
more physiologic conditions and with similar total protein concentrations. Norendoxifen 
inhibited placental aromatase with an IC50 value of 90 nM, while it inhibited human liver 
CYP2C9 and CYP3A with IC50 values of 990 and 908 nM respectively (Figure 7.6). 
Inhibition of human liver CYP2C19 by norendoxifen appeared even weaker, with less 
than 25% inhibition observed at concentrations up to 5 µM (Figure 7.6).  
Note: Experiments using human liver microsomes were performed by my colleagues 
Zifan Pei (CYP2C9) and Cong Xu (CYP2C19 and CYP3A) in the Department of 
Pharmacology and Toxicology here at Indiana University. 
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Figure 7.6. Selective inhibition of CYP isoforms by norendoxifen.  
In the presence of a range of norendoxifen concentrations, the remaining activity of 
human placental aromatase (dark circle), human liver CYP3A (open circle), human liver 
CYP2C9 (dark square) and human liver CYP2C19 (dark triangle) were determined by 
measuring the formation rates of metabolites from specific probe drugs and were 
expressed as percentage of control. Individual points represent the mean of three to four 
independent incubations. Source: Experiments using human liver microsomes were 
performed by my colleagues Zifan Pei (CYP2C9) and Cong Xu (CYP2C19 and CYP3A). 
The study design, experiments using placental aromatase and all data analysis were 
carried out by me.   
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Discussion  
These studies characterized inhibition of human aromatase in vitro by three 
tamoxifen metabolites: endoxifen, NDMT and norendoxifen. These findings have a 
number of implications. While the serum concentrations of endoxifen in humans are in 
the 10 - 150 nM range (Borges et al. 2006; Jin et al. 2005), tissue concentrations of 
endoxifen are higher, especially in breast tumors, where they appear to be 10 to 100 times 
more, i.e. about 1 - 15 µM (Lien et al. 1991). The inhibitory concentrations for endoxifen 
we observed in vitro (Ki of 4.0 µM) fall in the same range. Furthermore, in rats the ratio 
of endoxifen concentrations in uterus to those in serum has been reported to be at least 
20:1, and to be at least 500 : 1 between lung and serum (Lien, Solheim, and Ueland 
1991). NDMT concentration in human treated with tamoxifen is more than 10 times 
higher than that for endoxifen (Jin et al. 2005). These high tissue concentrations are 
consistent with the large apparent distribution volume for tamoxifen, the parent drug, 
which is about 50 to 60 L/kg in humans (Lien et al. 1989), indicating that most of the 
drug (99.9%) is present in peripheral compartments, and suggesting extensive tissue 
accumulation. This wide tissue distribution (Lien, Solheim, and Ueland 1991), and the 
relatively long apparent half lives of NDMT and endoxifen (~ 14 and 44 days 
respectively) (Jordan 1982; Johnson et al. 2004; Ahmad, Shahabuddin et al. 2010) in 
humans treated with tamoxifen are consistent with an extended period of tissue exposure. 
Sustained aromatase inhibition in vivo by these metabolites would therefore seem a 
possibility. 
Since the initial observations were carried out using an artificial, fluorometric 
substrate for aromatase, I examined the physiologic relevance of these data by testing the 
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ability of endoxifen to inhibit metabolism of the endogenous substrate of aromatase, 
testosterone. The inhibition of testosterone metabolism to estradiol was studied under 
conditions involving higher aromatase concentrations so that the generation of estradiol 
could be quantitatively monitored. A Ki of 178 µM for endoxifen was observed under 
incubation conditions that included a 6.7 fold higher enzyme concentration (50 nM). It is 
possible that endoxifen is less potent as an inhibitor of testosterone metabolism. An 
alternative explanation would be that this observed higher Ki is an artificial result of 
different experimental conditions. When I tested the latter possibility, two observations 
suggest that in conditions involving lower aromatase concentrations, testosterone 
metabolism may be inhibited by lower concentrations of endoxifen: (1) In the two 
experimental conditions tested, the IC50 of endoxifen for the same substrate, MFC, 
differed by 15 - 16 fold (6.1 µM at 7.5 nM aromatase, compared to 95 µM at 50 nM 
aromatase), suggesting a lower Ki at lower enzyme concentrations. (2) The Km for 
testosterone metabolism observed in this system was 4 µM, significantly higher than that 
(0.2 µM) reported in placental microsomes (Zharikova et al. 2006). It follows that under 
physiologic conditions, where the concentrations of aromatase and of testosterone in vivo 
are lower than those used in vitro, inhibition is likely to occur at relatively low inhibitor 
concentrations. 
Aromatase inhibition by endoxifen and NDMT was observed to be through a non-
competitive mechanism. This mechanism explains why it was possible for endoxifen to 
effectively inhibit testosterone metabolism, although the observed IC50 value for 
inhibition of MFC metabolism by testosterone was 19-fold lower than that of endoxifen 
(Table 7.1). A non-competitive mechanism means that there might be allosteric 
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interactions with aromatase. It is possible that endoxifen brings about non-competitive 
inhibition via a site remote from the substrate-binding site of aromatase, or that it could 
occur via interaction of two compounds that bind differently within the same catalytic 
site. The structure of the catalytic site of aromatase has been well studied through 
interactions between testosterone and this active site (Ghosh et al. 2010). Allosteric drug 
binding sites or regulatory regions of aromatase have not been considered until now. Of 
note, mutation of a site distant from the substrate-binding site has been shown to increase 
enzyme activity and reduce the susceptibility to inhibition of aromatase by 
aminoglutethimide (Payne et al. 2009). These observations raise the possibility that an 
allosteric mechanism might contribute to the pharmacologic regulation of aromatase and 
could be exploited to modulate aromatase activity for therapeutic benefit. 
Our studies also demonstrate that norendoxifen is a relatively potent and selective 
inhibitor of human aromatase with a Ki value in the nanomolar range, close to the 
potency of letrozole, which is the most potent aromatase inhibitor that is available for 
clinical use. Although norendoxifen is a known metabolite of tamoxifen in humans (Lien 
et al. 1991; Jin et al. 2005), little is known about its tissue concentrations or its 
contribution to tamoxifen effects. It is a minor metabolite of tamoxifen that exists at 
notably lower concentrations than the parent drug or its major metabolites, but our data 
make clear that it is a much more potent inhibitor of aromatase than the well-known 
metabolites, endoxifen and NDMT. In as much as these two major metabolites may 
contribute to tamoxifen action via aromatase inhibition, it is equally possible that 
norendoxifen contributes significantly to the clinical effects of tamoxifen. In addition, 
endoxifen itself is being developed as a drug (Ahmad, Ali et al. 2010; Ahmad, 
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Shahabuddin et al. 2010), and so the role of norendoxifen, the primary demethylated 
metabolite of endoxifen, in endoxifen action may be important for this reason. 
In this context it is important to note that endoxifen is a widely recognized and 
potent estrogen receptor modulator (Jin et al. 2005; Johnson et al. 2004; Jordan 2007). It 
follows that its demethylated metabolite, norendoxifen, may also act as an estrogen 
receptor ligand. However, the binding affinity of norendoxifen for estrogen receptors and 
the activity of norendoxifen at estrogen receptors, whether it is estrogenic or anti-
estrogenic, merit future studies. Tamoxifen therapy is known to have tissue-specific 
estrogen receptor modulation activities in humans. Such activities effectively limit 
estrogen signalling at breast tumors but preserve some estrogenic effects at other sites 
including the musculoskeletal and cardiovascular systems. Therefore, tamoxifen 
metabolites or their derivatives may therefore be valuable as alternative aromatase 
inhibitors that are able to mitigate the debilitating musculoskeletal toxicities experienced 
by breast cancer patients via tissue specific mechanisms. This possibility deserves further 
investigation.  
The metabolism of tamoxifen is complex (Johnson et al. 2004) and so its ultimate 
effects reflect the aggregation of the actions of multiple metabolites on the estrogen 
receptors, on aromatase and also possibly via other mechanisms that have been reported 
(Tian et al. 2009; da Rocha et al. 1999). The interpretation of these studies is limited by 
the difficulty of inferring drug concentrations at the effect site in vivo, given the 
acknowledged gradient between serum and tissue concentrations (Lien, Solheim, and 
Ueland 1991). As a result, the aggregated effect on aromatase activity in vivo and the 
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relative contributions of endoxifen, NDMT and norendoxifen to aromatase inhibition 
remain unclear. 
Our findings presented here could help explain a number of currently unexplained 
observations. (1) Inhibition of aromatase by tamoxifen metabolites in vitro is consistent 
with the observation that estrogen concentrations decreased on average in post-
menopausal women being treated with tamoxifen (Lonning et al. 1995). An alternative 
reason for such decrease would be effects downstream of estrogen receptor modulation 
by tamoxifen metabolites. (2) Inhibition of aromatase by tamoxifen metabolites might 
help explain why tamoxifen causes musculoskeletal pain, similar to that commonly 
experienced by patients taking aromatase inhibitors in some patients (Howell et al. 2005; 
Zivian and Salgado 2008). This side effect of tamoxifen appears debilitating and 
prominent in Asian women (Love et al. 1999). It is possible that, in the sub-population of 
post-menopausal women in whom musculoskeletal pain is a severe side effect of 
tamoxifen, aromatase inhibition by its metabolites is more prominent. Since 
musculoskeletal toxicities are less frequent in patients taking tamoxifen compared to AI 
therapies, aromatase inhibition by tamoxifen metabolites may not occur in every patient. 
(3) Aromatase inhibition by NDMT may help explain the inconsistency in observed 
associations between CYP2D6 genotype and outcomes in patients with breast cancer 
(Goetz et al. 2005; Wegman et al. 2007; Nowell et al. 2005). If aromatase inhibition 
contributes to the action of tamoxifen, then it is possible that this inhibition may 
confound simple associations between endoxifen concentrations and clinical outcomes. 
(4) Mechanistic studies that employ only 4HT, an estrogen receptor modulator that is not 
an aromatase inhibitor, may inadequately represent tamoxifen action in vivo.  
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Figure 7.7. Diagram of possible mechanisms underlying anti-estrogenic effects of 
tamoxifen and its metabolites based on in vitro data.  
NDMT, endoxifen and norendoxifen are able to act as aromatase inhibitors, while 4HT 
and endoxifen are the most potent antagonists at the estrogen receptor. 
 
Overall, our data identify a novel mechanism of tamoxifen action that may 
contribute to its efficacy in the treatment of breast cancer, and may help explain its side 
effects. Although the overall contribution of aromatase inhibition to tamoxifen action is 
110 
 
unclear at this point, the data emphasize that tamoxifen and endoxifen may have multiple 
pharmacologic effects that are mediated by their active metabolites. Most notably, a 
previously unrecognized active metabolite, norendoxifen, is a relatively potent and 
selective aromatase inhibitor. The balance between tamoxifen’s effects as an estrogen 
receptor modulator and as an aromatase inhibitor (Figure 7.7) may vary between 
individuals and across populations. This balance may contribute to the clinical effects of 
tamoxifen on serum and tissue estrogen concentrations, and may explain in part the 
variability in bone density, hot flashes, serum lipid concentration, severity of 
musculoskeletal pain and breast cancer recurrence observed in patients taking tamoxifen. 
Relationships between tamoxifen metabolite concentrations and clinical outcomes may 
be complex, and should be interpreted and studied with an open mind.  
 
Methods 
Fluorescent assay for inhibition of aromatase in vitro 
The activity of both recombinant and placental human aromatase was determined 
as described in “Chapter Ten: General Methods / Fluorescent assay for inhibition of 
aromatase in vitro”. 
 
Inhibition of testosterone metabolism by aromatase in vitro 
The activity of aromatase was determined by measuring the rate of conversion of 
testosterone to estradiol as described in “Chapter Ten: General Methods / Inhibition of 
testosterone metabolism by aromatase in vitro”. 
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Quantifications of estradiol formation 
High performance liquid chromatography (HPLC) assays with ultraviolet (UV) 
detection were developed for the quantification of testosterone conversion to estradiol as 
described in “Chapter Ten: General Methods / HPLC-UV assays for the quantifications 
of estradiol and EDDP formation”, with the modification that 25 μl of 25 µM letrozole 
was added to each sample as an internal standard. 
 
Inhibition of recombinant human CYP isoforms  
The activities of recombinant human CYP2C9, CYP2C19 and CYP2D6 were 
determined by measuring the conversion rates of their fluorometric substrates to the 
corresponding fluorescent metabolites as described in “Chapter Ten: General Methods / 
Inhibition of recombinant human CYP isoforms”. 
 
Inhibition of specific CYP isoforms using pooled HLMs 
Inhibition of CYP2B6, CYP2C9, CYP2C19 and CYP3A using pooled HLMs was 
determined by measuring the conversion rates of specific probe drugs to their metabolites 
as described in “Chapter Ten: General Methods / Inhibition of specific CYP isoforms 
using pooled HLMs”. The formation rates of 4-hydroxybupropion from bupropion, of 4-
hydroxytolbutamide from tolbutamide, of 5′-hydroxyomeprazole from omeprazole and of 
6-β hydroxytestosterone from testosterone served as markers of CYP2B6, CYP2C9, 
CYP2C19 and CYP3A activity respectively. 
 
 
112 
 
Kinetic analyses 
The rates of metabolite formation from substrate probes in the presence of the test 
inhibitors were compared with those for control in which the inhibitor was replaced with 
vehicle. The extent of aromatase inhibition was expressed as percent enzyme activity 
remaining compared to control. The percent of aromatase activity remaining at different 
inhibitor concentrations was used to estimate IC50 values when the substrate 
concentration was set at 25 µM. IC50 values were determined as the inhibitor 
concentration which brought about a 50% reduction in enzyme activity by fitting all the 
data to a one-site competition equation using Prism version 5.01 for Windows (GraphPad 
Software Inc., San Diego, CA).  
In order to estimate inhibition constants, formation rates of metabolite at different 
substrate concentrations were plotted as Dixon plots according to the following equation: 
 
where v is the velocity of reaction, [S] is the substrate concentration, [I] is the inhibitor 
concentration, Km is the Michaelis constant, and Vmax is the maximum reaction rate. The 
equilibrium dissociation constant of the inhibitor Ki was determined by estimating the 
corresponding value on the X-axis of the common intercept using linear regression.  
To further characterize the mechanism of inhibition, the same data were plotted as 
Eadie-Hofstee plots according to the following equation: 
 
where KSapp is the apparent Michaelis constant and  Vmaxi is the apparent maximum 
reaction rate in the presence of the inhibitor. The relationships between the slopes of 
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these lines generated by linear regression were used to determine the inhibitory 
mechanisms involved (Segel 1993).  
For non-competitive inhibition, in order to estimate KSapp and Vmaxi at different 
inhibitor concentrations, the same data were plotted as Lineweaver–Burk plots according 
to the following equation: 
 
Using linear regression, the intercepts on the X-axis were used to determine KSapp values 
and intercepts on the Y-axis were used to determine Vmaxi values.  
For competitive inhibition, all data on the formation rates of metabolite at 
different substrate concentrations were plotted as Lineweaver–Burk plots according to the 
following equation: 
 
Note: Equations are quoted from (Segel 1993). 
 
Note: The work described in this chapter has been published (Lu, Desta, and Flockhart 
2011; Lu, Xu et al. 2011).  
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CHAPTER EIGHT 
A New Conceptual Framework for Aromatase Inhibition 
 
Introduction 
To improve the treatment of breast cancer, there is a need to develop novel 
aromatase inhibitors (AIs) that have improved therapeutic window than those currently 
available. Improved AIs may bring about adequate aromatase inhibition, while limiting 
side effects. Since some of the tamoxifen metabolites can inhibit the activity of aromatase 
(Chapter Seven, this dissertation), these compounds represent important candidate 
structures in the search for novel and clinically useful AIs for three reasons. First, their 
structures are markedly different from any previously reported AIs, suggesting alternative 
biochemical mechanisms of action and also the possibility of improved benefit and 
toxicity profiles. Second, some of these compounds are able to bind to estrogen receptors. 
These metabolites may be able effectively reduce estrogen synthesis and at the same time 
modulate estrogen signaling by binding to estrogen receptors in a tissue-specific manner. 
Therefore, these structures or their derivatives may be valuable as alternative AIs that are 
able to mitigate the debilitating toxicities associated with estrogen depletion via tissue-
specific mechanisms. Third, these compounds are metabolites of a widely used drug, and 
many patients have already been exposed to them. To explore the ability of a range of 
structurally related tamoxifen metabolites to act as AIs, I tested and compared the activity 
of these compounds using recombinant human aromatase. Since these tamoxifen 
metabolites are structurally different from any known aromatase inhibitors, it would be 
important to understand the mechanism of action employed by these compounds. Thus, I 
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analyzed the structure-activity relationships of these compounds and estimated structure-
dependent interactions between these compounds and aromatase as a first step towards 
the development of lead candidates for novel inhibitors. 
Furthermore, in order to establish a lead optimization strategy, I collaborated with 
the laboratory of Professor Mark Cushman at Purdue University, and they used 
computerized molecular docking with the X-ray crystallographic structure of aromatase 
to describe possible biochemical interactions employed by tamoxifen metabolites, and 
also to explore other potential derivatives of the most potent inhibitor we identified as 
potential candidate structures. 
 
Results and discussion 
The ability of tamoxifen and its nine metabolites to inhibit recombinant human 
aromatase at an inhibitor concentration of 10 µM was tested and their activities were 
compared. While tamoxifen itself was not able to inhibit aromatase, many tamoxifen 
metabolites were capable of doing so. Figure 8.1 shows the relative potency of tamoxifen 
and its available metabolites as AIs. Among the primary metabolites, N-desmethyl-
tamoxifen, 4’-hydroxy-tamoxifen and tamoxifen-N-oxide were all relatively weak 
inhibitors. Among the secondary metabolites of tamoxifen, endoxifen and 4,4’-
dihydroxy-tamoxifen were more potent inhibitors than the primary metabolites. 
Interestingly, a tertiary metabolite, norendoxifen, was the most potent of all the inhibitors 
tested, and the only metabolite that completely inhibited enzyme activity at 10 µM. 
The inhibitory potency order of the tested compounds was as follows: 
norendoxifen >> 4,4’-dihydroxy-tamoxifen > endoxifen > N-desmethyl-tamoxifen, N-
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desmethyl-4'-hydroxy-tamoxifen, tamoxifen-N-oxide, 4'-hydroxy-tamoxifen, N-
desmethyl-droloxifene > 4–hydroxy-tamoxifen, tamoxifen. Consideration of the 
structure-activity relationships generated by these data makes clear that a number of 
consistent relationships exist. As methyl groups are progressively removed, inhibitory 
potency of a compound increases substantially, while the addition of a single hydroxyl 
group also increases potency (Figures 8.1 and 8.2). 
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Figure 8.1. Relative potency of tamoxifen and its primary, secondary and tertiary 
metabolites in the inhibition of aromatase.  
Test compounds (10 µM) were incubated with 7.5 nM recombinant human aromatase at 
37 °C for 30 min. Letrozole (0.1 µM) and vehicle (acetonitrile) were used as positive and 
negative controls respectively. Data are plotted as means of triplicate incubations with 
standard deviations. The dotted line represents 100 percent activity that was observed 
with the vehicle control.  
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Figure 8.2. Structure-function relationships: stepwise hydroxylation and 
demethylation of tamoxifen progressively increase the potency of aromatase 
inhibition.  
The horizontal open arrows represent the addition of a hydroxyl group. The vertical dark 
arrows represent the removal of a methyl group.  Available compounds tested were: (1) 
tamoxifen; (2) 4-hydroxy-tamoxifen; (3) 4’-hydroxy-tamoxifen; (4) 4,4’-dihydroxy-
tamoxifen; (5) N-desmethyl-tamoxifen; (6) N-desmethyl-4-hydroxy-tamoxifen  or 
endoxifen, (7) N-desmethyl-4'-hydroxy-tamoxifen; (8) N,N-didesmethyl-4-hydroxy-
tamoxifen or norendoxifen 
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Table 8.1. Calculated binding free energy for most stable docking poses (MM-
BPSA) and the experimental IC50 values of compounds. 
 
Note: *, IC50 values were determined when mixtures of unseparated (E) and (Z) isomers 
were tested. The data on experimental IC50 values were generated by me and the data on 
calculated binding free energy were from the Cushman Lab at Purdue University. 
 
Based on the structure-function relationships that I proposed, a series of molecular 
modeling studies were performed in collaboration with the Cushman Lab at Purdue 
University to study the biochemical mechanisms by which tamoxifen metabolites inhibit 
aromatase. These investigators docked proposed compounds into the active site of 
aromatase (PDB ID 3eqm) (Ghosh et al. 2010) using GOLD software (Verdonk et al. 
2003) and the energies of the complexes were minimized using the Amber force field and 
Amber charges. The binding free energies calculated by them are summarized together 
with my experimental aromatase IC50 values in Table 8.1. These estimated free energies 
appeared positively associated with the relative inhibitory potencies observed. They also 
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validated this docking and energy minimization procedure by reproducing the published 
crystal structure of aromatase-androstenedione complex by extracting the ligand structure 
and then docking it back into the aromatase active site, merging the highest-scored 
binding pose with the protein, and then minimizing the complex energy following the 
same protocol used with other tamoxifen metabolites. The root mean standard deviation 
between the structure of the newly generated complex derived from molecular modeling 
and the original crystal structure (PDB ID 3eqm) was 1.73 Å.  
In order to further characterize the activity of the most potent inhibitor--one that 
might represent a lead compound to guide future rational drug design--we studied the 
hypothetical binding modes of the norendoxifen isomers using computerized molecular 
docking models produced by our collaborators at Purdue University. Both isomers have 
similar binding modes, with the phenolic hydroxyl groups of both isomers bind to the 
carbonyl group of Met374 (Figures 8.3 and 8.4). The other oxygen atoms of both forms 
are calculated to exist near the iron atom; however, the ether oxygen atom of the E 
isomer was calculated to be 0.8 Å closer to the iron atom with better directionality for 
binding than the Z form. A hydrogen bond is apparent between the terminal aliphatic 
amino group in the E form and the carbonyl group of Ala306. A similar interaction is not 
predicted for the Z form, in which the terminal aliphatic amino nitrogen atom was 
calculated to at least 5 Å away from the closest atom that it could hydrogen bond to. 
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Figure 8.3. Hypothetical binding mode of (E)-norendoxifen in the human aromatase 
active site (PDB ID 3eqm).  
The ligands are gray, with oxygen depicted in red and nitrogen in blue. The protein is 
colored green, and the heme is colored magenta. Yellow dashed lines represent the 
distances between hydrogen bond donors and acceptors. The stereoview is programmed 
for wall-eyed (relaxed) viewing. Source: from the Cushman Lab at Purdue University. 
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Figure 8.4. Hypothetical binding mode of (Z)-norendoxifen in the human aromatase 
active site (PDB ID 3eqm).  
The ligands are gray, with oxygen depicted in red and nitrogen in blue. The protein is 
colored green, and the heme is colored magenta. Yellow dashed lines represent the 
distances between hydrogen bond donors and acceptors. The stereoview is programmed 
for wall-eyed (relaxed) viewing. Source: from the Cushman Lab at Purdue University. 
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Figure 8.5. Hypothetical binding mode of 4,4'-dihydroxy-tamoxifen in the human 
aromatase active site (PDB ID 3eqm).  
The ligands are gray, with oxygen depicted in red and nitrogen in blue. The protein is 
colored green, and the heme is colored magenta. Yellow dashed lines represent the 
distances between hydrogen bond donors and acceptors. The stereoview is programmed 
for wall-eyed (relaxed) viewing. Source: from the Cushman Lab at Purdue University. 
 
On the other hand, the unsubstituted phenyl ring and the ethyl moiety in both E 
and Z forms are surrounded by hydrophobic residues including Phe221, Leu477, Val370, 
Ile70, and the benzene ring of Trp224. In addition, the phenyl ring that contains the 
hydroxyl group is calculated to from a possible side-to-face stacking interaction with 
Phe134 in both isomeric forms. A comparison of the two complexes reveals that the ethyl 
and phenyl groups switch locations, but the two remaining phenyl rings that contain 
hydrogen bonding substituents maintain their positions.  
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In this study, a number of tamoxifen metabolites were shown to have activity as 
AIs with a wide range of potencies. Although these studies are limited to the 
commercially available tamoxifen metabolites, they are sufficient to allow the 
exploration of relationships between the structures of the compounds we tested and their 
function. The data indicate that stepwise hydroxylation and demethylation of tamoxifen 
both resulted in progressive increases in inhibitory potency (Figures 8.1 and 8.2). This is 
consistent with the collaborative data from Mark Cushman’s Lab: The activities of 4-
hydroxy-tamoxifen (Figure 8.2 Structure 2, IC50 530 µM), endoxifen (Structure 6, IC50 6 
µM), and norendoxifen (Structure 8, IC50 30 nM) show that sequential N-demethylation 
results in a very significant increase in aromatase inhibitory potency. The molecular 
models (Figures 8.3 - 8.5) document limited space available in the ligand binding site 
surrounding the amine, and the decrease in activity observed with the presence of more 
methyl groups can be attributed to steric factors. The models displayed in Figures 8.3 and 
8.4 indicate that the amino groups of both isomers are hydrogen bonded to the carbonyl 
oxygen atom of Ala306. This suggests that the loss of activity seen with the methylation 
of the amine may also result from a decrease in its capacity to act as a hydrogen bond 
donor toward the Ala306 carbonyl oxygen. The models displayed in Figures 8.3 and 8.4 
also indicate that the unsubstituted phenyl rings and ethyl groups of the double bond 
isomers of norendoxifen are buried in hydrophobic cavities. In the in vitro experimental 
data, the E and Z/E mixture of norendoxifen appeared to have the same enzyme 
inhibitory activities suggesting that the activities of the Z and E isomers are equal. The 
similar activities of the two isomers and the perspective offered by the molecular models, 
suggest that the locations of the phenyl and ethyl groups can be switched with no change 
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in activity. Of note, it is suggested by Dr. Mark Cushman that the ethyl and unsubstituted 
phenyl groups therefore appear to contribute to enzyme affinity through the presence of 
general hydrophobic and dispersion (van der Waals) interactions, as opposed to being due 
to specific interactions with particular amino acid side chains of the enzyme. Overall, the 
data suggest that the double bond stereochemistry in this series of AIs may not have a 
large impact on biological activity, although smaller effects remain possible, since in 
silico, the molecular models did indicate a greater calculated binding free energy for the 
Z isomer (Table 8.1). More research is needed in order to determine the precise 
enantioselectivity of this compound.  
Comparison of the activities of N-desmethyl-tamoxifen (Figure 8.2 Structure 5, 
IC50 20 µM) and endoxifen (Structure 6, IC50 6 µM) documents a positive contribution 
made by the 4-hydroxyl group. The molecular models suggest that this may reflect 
hydrogen bonding of the phenol with the carbonyl of Met374. Furthermore, comparison 
of the activities of 4-hydroxytamoxifen (Structure 2) and 4,4'-dihydroxy-tamoxifen 
(Structure 4) represented in Figure 8.1 indicates that the 4'-hydroxyl group makes a large 
positive contribution to the activity. The hypothetical model of the complex of human 
aromatase with 4,4'-dihydroxy-tamoxifen (Structure 4) suggests that the 4'-hydroxyl 
groups contribute to the affinity of the ligand through hydrogen bonding with the 
carbonyl oxygen of Asp309 (Figure 8.5).  
These results lead us to postulate that modifications to the basic triphenylalkene 
structure of tamoxifen (Figure 8.6) that preserve hydrogen bonding to the Ala306, 
Met374 and Asp309 residues might be a valuable approach in the development of the 
next generation of AIs. Of note, the specific interactions described here with Ala306 and 
126 
 
Met374 were also noted as being key to favorable interactions between aromatase and a 
series of other ligands (Punetha, Shanmugam, and Sundar 2011). In this context, since 
norendoxifen is a potent and selective inhibitor in vitro (Chapter Seven Figures 7.5 and 
7.6), it merits further investigation as a clinical AI, and may be able to serve as a lead 
compound for the rational design of new therapeutic agents for breast cancer.  
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Figure 8.6. The new structural basis for the development of improved aromatase 
inhibitors. 
This basic triphenylalkene structure was developed based on the structures of tamoxifen 
metabolites. The oxyalkylamine side chain on the phenyl group may have structural 
variants including: length in -(CH2)n-, n = 1, 2, 3, 4 or 5, such as CH2-CH2-, CH2-CH2- 
CH2-, CH2-CH2-CH2- CH2-and  CH2-CH2-CH2-CH2- CH2-, position on the phenyl group; 
position of oxygen in relation to -(CH2)n- chain; and oxyalkene composition of the side 
chain; R1 may be independently selected from the group consisting of H, CH3 and OH; R2 
and R3 are independently selected from the group consisting of H, CH3-, CH3-CH2-, CH3-
CH2-CH2-; R4 is selected from the group consisting of: H, CH3-, CH3-(CH2)n-, hydroxy, 
methoxy, ethoxy; and n = 1, 2, 3, 4 or 5. 
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In summary, the range of structures tested in this study and their pharmacologic 
potencies provide a reasonable pharmacophore upon which to build novel aromatase 
inhibitors. Based on these findings, a series of compounds that have triphenylalkene 
structure with side chain(s) on the phenyl group(s) that are oxyalkanes or oxyalkenes and 
that terminate in an unsubstituted or mono-substituted amine (Figure 8.6) can be 
exploited as new inhibitors for aromatase. These structures may have the potential to 
provide benefit to patients who are treated with AIs for breast cancer and other conditions 
by expanding their treatment options with the goal of enhancing treatment efficacy and 
reducing toxicity. Most of all, norendoxifen may be able to serve as a potent and selective 
lead compound in the rational design of improved AIs.  
 
Methods 
Fluorescent assay for inhibition of aromatase in vitro 
The activity of aromatase was determined by measuring the conversion rate of a 
fluorometric substrate to its fluorescent metabolite as described in “Chapter Ten: General 
Methods / Fluorescent assay for inhibition of aromatase in vitro”. 
 
Computerized molecular modeling 
Computerized molecular docking with the X-ray crystallographic structure of 
aromatase was performed in collaboration with Mark Cushman Lab at Purdue University 
as described in “Chapter Ten: General Methods / Computerized molecular modeling”. 
 
Note: The work described in this chapter has been published (Lu, Xu et al. 2011).  
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CHAPTER NINE 
Conclusions and Future Directions 
 
Aromatase as a drug-metabolizing enzyme in humans 
The studies presented here are the first to directly test the effects of aromatase 
inhibition on drug disposition in humans and demonstrate that aromatase may be in part 
responsible for the metabolism of methadone. The data indicate that, on average, 
aromatase seems to account for ~ 22% of the clearance of a single dose of methadone (2 
mg) in a group of post-menopausal women (Chapter Three, this dissertation). The 
discovery of this new metabolic route for methadone improves our understanding of 
methadone clearance, and emphasizes that aromatase can serve as a drug-metabolizing 
enzyme, beyond its important role in catalyzing endogenous steroid synthesis.  
Our data also indicate that the decrease in methadone clearance brought about by 
aromatase inhibition is variable in the group of people studied, suggesting that there 
might be variability in the relative contribution of aromatase to overall methadone 
clearance in individual people. The balance between aromatase and other enzymes in 
contribution to methadone metabolism may be different among people. Mechanisms 
underlying the large variability in methadone pharmacokinetics may be complex and 
might involve factors that influence aromatase activity. 
The studies presented in this work also suggest a broader clinical role for 
aromatase in the disposition of xenobiotics. A quantitatively important role for aromatase 
in drug metabolism raises the possibility of clinically meaningful pharmacokinetic drug-
drug interactions with aromatase inhibitors that would not otherwise have been 
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anticipated, especially in patients taking aromatase inhibitors for a range of indications 
including breast cancer, the treatment of infertility and other off-label uses.  
 
A novel structural basis for the development of improved aromatase inhibitors 
There is a need for alternative aromatase inhibitors that bring about adequate 
enzyme activity inhibition, while limiting treatment side effects. By testing a carefully 
selected group of xenobiotics for their ability to inhibit aromatase, this work 
demonstrates that, in contrary to conventional wisdom, which holds that aromatase has 
strict ligand requirements, aromatase interacts with a structurally wide range of 
compounds other than the known endogenous substrates or the current inhibitors. These 
compounds include methadone and its metabolites EDDP and EMDP, tamoxifen and a 
number of its metabolites, fluoxetine, naringenin and 17-hydroxy exemestane. Among 
these compounds, a number of novel aromatase inhibitors that employ diverse kinetic 
mechanisms have been identified and characterized. Data indicate that methadone (KI of 
40.6 ± 2.8 μM; kinact of 0.061 ± 0.001 min-1) and its major metabolites are mechanism-
based inhibitors (Chapter Five Figure 5.2), naringenin (IC50s of 2.8 μM for (R)-
naringenin and 1.4 μM for (S)-naringenin) is a stereoselective inhibitor (Chapter Six 
Figure 6.2), endoxifen (Ki of 4.0 μM) and N-desmethyl-tamoxifen (Ki of 15.9 μM) are 
two non-competitive inhibitors (Chapter Seven Figures 7.2 and 7.3), and norendoxifen 
(Ki of 35 nM) is a relatively potent, selective, and competitive inhibitor (Chapter Seven 
Figures 7.5 and 7.6). These findings illuminate the biochemistry and pharmacology of 
aromatase. Of note, the biochemical mechanism of inhibition by some of these 
metabolites is allosteric, suggesting that there might be an alternative site that could be 
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exploited in the search for new therapies to modulate aromatase activity. The range of 
structures tested in this work and their different pharmacological properties provide a 
reasonable pharmacophore upon which to build improved aromatase inhibitors. 
In the search for better aromatase inhibitors, my work demonstrates that 
tamoxifen metabolites represent important candidate structures. They are a series of 
compounds that have triphenylalkene structure with side chain(s) on the phenyl group(s) 
that are oxyalkanes or oxyalkenes and that terminate in an unsubstituted or mono-
substituted amine (Chapter Eight Figure 8.6). Based on the observed various potencies of 
these compounds, several consistent structure-function relationships exist: stepwise 
demethylation and hydroxylation of tamoxifen both progressively increase the potency of 
the compound as an aromatase inhibitor (Chapter Eight Figures 8.1 and 8.2). My work 
also shows that the most potent inhibitor identified, norendoxifen, is a relatively selective 
aromatase inhibitor, when its inhibitory effects on clinically important cytochrome P450 
enzymes were tested and compared (Chapter Seven Figure 7.6). In addition, collaborative 
data generated using molecular modeling improve our understanding of possible 
biochemical mechanisms employed by norendoxifen to interact with the active site of 
aromatase. These findings, together with the structure-function relationships identified, 
suggest that modification to the basic triphenylalkene structure of tamoxifen that 
preserves hydrogen bonding to the Ala306, Met374 and Asp309 residues of the active 
site might be a valuable approach in the rational design of new and effective aromatase 
inhibitors that work by a similar mechanism. In this context, norendoxifen may be able to 
serve as a lead compound for the development of drugs with improved therapeutic index.  
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Clinical implications 
This work has a number of potentially important clinical implications. The new 
roles for aromatase in drug disposition and pharmacokinetic drug-drug interactions 
described herein may help optimize therapy and prevent toxicity. 
First, improved understanding of interactions between methadone and aromatase 
may help explain a few clinical observations. Methadone dosing is difficult to manage 
and unanticipated accumulation of methadone in patients can lead to high methadone 
concentrations with resultant potentially lethal consequences. Since methadone is both a 
substrate and a mechanism-based inhibitor of aromatase (Chapters Two and Five, this 
dissertation), methadone accumulation over time due to auto-inhibition of its own 
metabolism seen in some patients (Morton 2007) may be a result of the irreversible 
inhibition of aromatase by itself. Consistent with inhibition of aromatase by methadone, 
lower concentrations of estradiol and of follicle-stimulating hormone have been 
documented in men taking methadone (Hallinan et al. 2009), and low bone mineral 
density that may be due to low estrogen concentrations has been documented in 83% of 
patients in a methadone maintenance treatment program (Kim et al. 2006). This improved 
understanding of interactions between aromatase and methadone may help us develop 
new and rational strategies to prevent methadone overexposure. On the other hand, 
aromatase activity has large interindividual variability, and so the identification of a 
metabolic route for methadone via this enzyme may help to anticipate and manage 
withdrawal in multiple clinical settings where current predictive ability is low. These 
include the withdrawal that neonates of methadone-treated mothers’ experience (Serane 
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and Kurian 2008), methadone withdrawal that often occurs during pregnancy (Pond et al. 
1985), and that occurs in routine use of methadone to treat pain or heroin addiction.  
Second, tamoxifen is an important treatment for breast cancer, whose activity is 
known to be mediated via active metabolites, primarily by endoxifen which blocks 
estrogen binding to estrogen receptors. Our work demonstrates that some tamoxifen 
metabolites also act as aromatase inhibitors (Chapters Seven and Eight, this dissertation), 
suggesting that blockade of estrogen production may also contribute to the clinical effects 
of tamoxifen. This effect may explain the changes in serum and tissue estrogen 
concentrations seen in patients taking tamoxifen (Lonning et al. 1995). These data also 
improve our understanding of possible relationships between concentrations of active 
tamoxifen metabolites and clinical outcomes of tamoxifen therapy. For example, if 
aromatase inhibition contributes to the action of tamoxifen, then it is possible that this 
effect confounds a simple association between endoxifen concentration and clinical 
outcome. Aromatase inhibition mediated by multiple active tamoxifen metabolites may 
help explain the inconsistency in observed associations between CYP2D6 genotype and 
treatment outcome in breast cancer patients taking tamoxifen (Goetz et al. 2005; Nowell 
et al. 2005; Wegman et al. 2007). There may be a variable balance among patients 
between the blockage of estrogen production and the antagonism at estrogen receptors. 
This balance may therefore explain in part the variability in bone density, serum lipid 
concentrations, experience with hot flashes, severity of musculoskeletal pain and breast 
cancer recurrence observed in patients taking tamoxifen. 
Third, the novel aromatase inhibitors and their mechanisms of action identified 
here may contribute to the search for new approaches to breast cancer therapy both in the 
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treatment and prevention settings. For example, data suggest that medications, such as 
methadone and tamoxifen, are commonly taken by breast cancer patients, and may exert 
adequate aromatase inhibition beneficial in the prevention of tumor growth and cancer 
recurrence. Such effects may augment the treatment of breast cancer and may be 
therapeutically useful. Naringenin is often ingested via fruit products such as grapefruit 
juice and therefore might also be protective for people at risk for breast cancer. 
Lastly, inhibition of aromatase by the inhibitors identified in this work might 
occur in vivo and therefore may alter the metabolism of endogenous testosterone and 
androstenedione. As a result, side effects of these drugs, such as flushing, muscle pain 
and symptoms reminiscent of estrogen withdrawal (Senay 1985; Backstrom 1995), may 
be explained in part by the drugs’ action on aromatase.   
Overall, our findings have the potential to improve the use of methadone, 
tamoxifen and current aromatase inhibitors, all of which are commonly co-prescribed 
with a wide range of other drugs. These findings also improve our understanding of the 
potential clinical effects of the studied xenobiotic medications and dietary compounds on 
aromatase activity. As a result, it may be possible to more consistently treat patients, 
particularly in breast cancer, with current medications in ways that maximize efficacy, 
minimize side effects, better anticipate drug interactions and therefore improve the 
quality of life of patients. 
 
Future directions  
Based on the findings of my work, it would be valuable to further evaluate the 
following in the future: 
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(1) To investigate the influence of genetic variants of aromatase on methadone 
metabolism in humans. The results of the current study indicate that methadone is 
metabolized by aromatase in humans but the effect of aromatase inhibition on systemic 
methadone clearance is highly variable (Chapter Three, this dissertation). The relative 
contribution of aromatase and other enzymes suggested to be important in the metabolism 
of methadone, including particularly CYP2B6 (Crettol et al. 2005; Wang et al. 2011), 
may be influenced by genetic variants of aromatase and those of CYP2B6. This balance 
may be an important factor in the under- or over-dosing often seen in methadone patients. 
Future genetic studies both in vitro and in vivo that address the relationships between 
enzyme genotype and its quantitative contribution to overall methadone clearance should 
be performed. In the case of aromatase, several variants that influence its activity have 
been reported. The most widely studied is a tetranucleotide (TTTA)n tandem repeat 
polymorphism located in intron 4 of the human CYP19A1 gene, and it has been reported 
that the number of TTTA repeats is associated with estrogen levels (Somner et al. 2004), 
age at menarche (Xita et al. 2010), obesity (Hammoud et al. 2010), polycystic ovarian 
syndrome (Hao et al. 2010), risks for breast cancer (Ahsan et al. 2005; Kristensen et al. 
2000) and osteoporosis (Gennari et al. 2004; Masi et al. 2001). There have also been a 
few reports of a very rare autosomal recessive disease, human aromatase deficiency, 
caused by loss-of-function mutations in the CYP19A1 gene (Bulun 2000; Belgorosky et 
al. 2009; Rochira and Carani 2009). Interindividual variability in methadone dosage 
requirement has been shown to be polygenetic and cannot be explained by a single-gene 
effect (Hung et al. 2011). Demonstrating a clinically relevant relationship between 
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aromatase genotype and methadone clearance across multiple doses of the drug will help 
to achieve safer use of methadone. 
(2) To investigate the involvement of aromatase in the clinical disposition of other 
drugs. This work has shown that aromatase is responsible for methadone metabolism in 
humans. Placental aromatase has also been implicated in the metabolism and specifically 
the demethylation of buprenorphine (Deshmukh, Nanovskaya, and Ahmed 2003) and 
cocaine (Osawa et al. 1997) in vitro, it is therefore reasonable to directly examine the role 
that this enzyme plays in the metabolism of these drugs in clinical settings. Since the 
biochemical mechanism by which aromatase catalyzes the metabolism of either 
endogenous substrates or exogenous drugs involves the removal of a methyl group, it 
follows that other medications that are similarly metabolized may also be aromatase 
substrates. In particular, the results generated from screening compounds for aromatase 
inhibitors indicate that fluoxetine interacts with aromatase in vitro (Chapter Four Figure 
4.1.B). Fluoxetine is also a drug that primarily undergoes N-demethylation to 
norfluoxetine and aromatase might be involved in the biotransformation of this drug. This 
possibility deserves further study. 
(3) To further investigate the potential of norendoxifen as a clinically useful 
aromatase inhibitor. First, the current study has characterized norendoxifen as a potent 
and selective inhibitor in vitro (Chapter Seven Figures 7.5 and 7.6). The next step is to 
assess whether or not this action of norendoxifen is likely to happen in vivo. Although 
norendoxifen is a known metabolite of tamoxifen in humans (Lien et al. 1991; Jin et al. 
2005), little is known about its tissue concentrations or its contribution to tamoxifen 
effects. While norendoxifen is a tertiary metabolite of tamoxifen and its in vivo 
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concentration is probably at notably lower concentrations than the parent drug or its 
major metabolites, it is known that tamoxifen metabolites concentrate in tissue 
compartments. For example, the concentrations of endoxifen in breast tumors appear to 
be 10 to 100 times higher than its serum concentrations in humans (Lien et al. 1991). This 
serum-tissue gradient is more prominently shown by studies in rats. The ratio of 
endoxifen concentrations in tissue to those in serum can be as high as 500 : 1 (Lien, 
Solheim, and Ueland 1991). It follows that tissue accumulation of norendoxifen and 
thereby local aromatase inhibitions in vivo seem a possibility. In order to evaluate the 
contribution of norendoxifen to the therapeutic effects of its parent drug, tamoxifen or 
endoxifen, it is important to determine the serum and tumor concentrations of 
norendoxifen in people who undergo these therapies for breast cancer. The potency of 
this mechanism in vivo merits future studies. Second, it is important to note that 
norendoxifen is the metabolite of endoxifen and 4-hydroxy-tamoxifen, two widely 
recognized and potent estrogen receptor modulators (Jin et al. 2005; Johnson et al. 2004; 
Jordan 2007). It follows that norendoxifen may also act as an estrogen receptor ligand, 
that is able to modulate estrogen signaling. Studies should be carried out to determine the 
ability of norendoxifen to bind to estrogen receptors, and to assess its effects on estrogen 
signaling. The present studies demonstrate that norendoxifen is not only an aromatase 
inhibitor with potency close to letrozole, but that it also has the potential ability to 
mitigate the debilitating musculoskeletal toxicities experienced by breast cancer patients 
via tissue specific mechanisms involving estrogen receptor signaling. For example, a new 
aromatase inhibitor that is also an agonist at estrogen receptors in bone may prevent the 
high prevalence of vertebral fractures seen in breast cancer patients starting aromatase 
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inhibitor therapy (Bouvard et al. 2011). Norendoxifen and its derivatives may therefore 
be valuable candidates for a dual-mechanism therapy involving both aromatase inhibition 
and selective estrogen receptor modulation, which might be exploited in the development 
of alternative breast cancer therapies.  
(4) To investigate the influence of genetic variants of aromatase on its 
susceptibility to inhibition by different inhibitors. Aromatase inhibition has become the 
standard of care for ER-positive (~ 70% of all) breast cancer (Taylor and Muss 2010; 
Howell and Dowsett 1997). Although this therapy remains the most clinically effective 
treatment in preventing breast tumor growth and cancer recurrence, about 50% of all 
patients taking aromatase inhibitors in the adjuvant setting still recur within 5 years after 
surgery (Howell et al. 2005). There is a large variability in patients’ response to current 
aromatase inhibitors, both in efficacy and side effects. It is possible that genetic 
biomarkers such as aromatase genotype can help identify patients who benefit from this 
therapy and those who don’t. The reason for this difference is likely to be the influence of 
genetic variants on the 3-D structure of aromatase and therefore on its susceptibility to 
inhibition. Therefore, the susceptibility of aromatase variants to different inhibitors may 
be different, and it is possible to develop stratification strategies to identify the optimal 
aromatase inhibitor for individual breast cancer patients based on their genetic 
information. With the ongoing search for new aromatase inhibitors, a large number of in 
vitro aromatase inhibitors have been identified. These findings provide a pool of 
candidate compounds for in vitro testing on various aromatase variants. In this work, 
endoxifen and NDMT have been characterized as aromatase inhibitors via a non-
competitive mechanism, which is consistent with an allosteric interaction with aromatase 
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(Chapter Seven Figures 7.2 and 7.3). It is possible that this allosteric inhibition occurs via 
interactions at a site remote from the catalytic site of the enzyme, or that it occurs via 
interactions of two drugs that bind differently within the active site. Of note, mutation of 
a site distant from the substrate binding site of aromatase has been shown to increase 
enzyme activity and reduce the susceptibility to inhibition of aromatase by 
aminoglutethimide (Payne et al. 2009). These observations raise the possibility that 
allosteric mechanisms might contribute to the pharmacologic regulation of aromatase and 
could be exploited to modulate aromatase activity for therapeutic benefit. The knowledge 
of using selective aromatase inhibitors to overcome genetic influence will help develop 
diagnostic tests that could be used in a personalized approach to treat breast cancer. 
(5) To identify new biomarkers that can distinguish breast cancer patients who are 
destined to experience debilitating toxicity or benefit from treatment with aromatase 
inhibitors. Not all patients respond favorably to aromatase inhibition. In the long term, 
biomarker-guided individualization of therapy for cancer holds great promise to improve 
treatment outcomes. Breast cancer mortality is increasing rapidly in Asia while 
decreasing in Western countries (Aihara et al. 2010; Deapen et al. 2002). Many effective 
therapies, developed exclusively in Caucasians, have not been optimized for Asian 
patients despite the fact that there are many ethnic differences in breast cancer. These 
include the prevalence of molecular subtypes of the disease, genetic polymorphisms in 
pathways involved in estrogen biosynthesis and metabolism, vulnerability to debilitating 
side effects of anti-estrogenic therapies, pharmacokinetic-pharmacodynamic 
relationships, and effects of demographic factors (Toi et al. 2010; Miyoshi and Noguchi 
2003). As a result, personalized approaches guided by genomic and other biomarkers 
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seem particularly promising in improving breast cancer treatments, especially in Asian 
populations. It is well-known that in a subset of patients aromatase inhibition therapy is 
either ineffective or brings about musculoskeletal pain which results in poor quality of 
life and thereby non-compliance. In fact, 25 - 50% of women prescribed an aromatase 
inhibitor have been reported to stop taking the drug within 3 years (Ziller et al. 2009; 
Partridge et al. 2008; Hershman et al. 2010), and more than 50% of patients experience 
musculoskeletal pain, the principal reason for non-adherence (Zivian and Salgado 2008; 
Oberguggenberger et al. 2011; Aihara et al. 2010). In order to identify inherited 
pharmacogenetic variants that associate with treatment response, prospective and 
retrospective clinical studies can be designed and conducted using an informed genome-
wide association (GWA) approach. Genetic variants to be tested should include those 
suggested by prior broad GWA studies (Ingle et al. 2010), as well as variants in candidate 
genes involved in estrogen biosynthesis, metabolism and signaling pathways (Mao et al. 
2011). Clinical response can be assessed by measuring musculoskeletal toxicity using the 
Health Assessment Questionnaire (Thompson and Pegley 1991) and Visual Analogue 
Pain Rating Scale (Henry et al. 2010), and by analyzing data on cancer recurrence from 
patients’ medical records. These studies will identify novel biomarkers that can be 
combined in diagnostic tests and that inform future stratification of breast cancer therapy. 
 
Summary  
Cytochrome P450s in humans are enzymes responsible for the metabolism and 
elimination of the majority of therapeutic xenobiotics. One member of this class of 
enzymes, aromatase (CYP19), is less known for its interactions with xenobiotics. Our 
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studies presented here demonstrate potentially important roles for aromatase in drug 
disposition and pharmacokinetic drug-drug interactions. Specifically, this work discovers 
an involvement of aromatase in the metabolic pathways of methadone and improves our 
understanding of the pharmacologic action of tamoxifen. In addition, aromatase 
represents a key target in the treatment of a number of estrogen-related conditions 
including breast cancer. This work provides a new mechanistic framework for targeting 
aromatase by characterizing novel aromatase inhibitors that employ diverse kinetic 
actions. As a result, the range of tested structures and their attendant pharmacologic 
potencies provides a reasonable pharmacophore upon which to build novel aromatase 
inhibitors.  
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CHAPTER TEN 
General Methods 
 
Chemicals and reagents 
(R) / (–)-methadone and (S) / (+)-methadone were generously provided by the 
National Institute on Drug Abuse Drug Supply Program (Bethesda, MD). Methadone 
metabolites 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) iodide and 2-
ethyl-5-methyl-3,3-diphenylpyrroline (EMDP) hydrochloride were obtained from Alltech 
(Deerfield, IL). (R)-, (S)- and rac-naringenin were generously provided by Dr. Salvatore 
Caccamese at the Dipartimento di Scienze Chimiche, Università di Catania, Italy. 
Tamoxifen, all tamoxifen metabolites, bupropion, 4-hydroxybupropion, (R)-
hydroxyomeprazole, (R)-lansoprazole, norgestrol, nevirapine and letrozole were obtained 
from Toronto Research Chemicals Inc. (North York, ON, Canada). Racemic methadone 
hydrochloride, desmethyldiazepam, 17-β-estradiol, testosterone, (R)-omeprazole, 
tolbutamide, 4-hydroxytolbutamide, chloropropamide, β-NADP, glucose-6-phosphate 
dehydrogenase, and glucose-6-phosphate were purchased from Sigma-Aldrich (St. Louis, 
MO). Monobasic and dibasic sodium phosphate, monobasic potassium phosphate, 
magnesium chloride, HPLC-grade methyl tert-butyl ether, acetonitrile and methanol were 
purchased from Fisher Scientific (Pittsburgh, PA). Glycine (electrophoresis purity 
reagent) was obtained from Bio-Rad Laboratories (Hercules, CA, USA). All drug 
solutions were prepared by dissolving each compound in methanol or acetonitrile, and 
were stored at − 20 °C. Tamoxifen and its metabolites were prepared under dim light and 
in brown tubes to minimize photodegradation. 
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Baculovirus-insect cell-expressed human aromatase (with oxidoreductase) 
microsomal preparations, pooled human liver microsomes (HLMs) and the cytochrome 
P450 inhibitor screening kits for aromatase (CYP19), 2C9, 2C19 and 2D6 were 
purchased from BD Biosciences (San Jose, CA). Placental microsomal preparations were 
a generous gift from Dr. Mahmoud S. Ahmed at the University of Texas Medical Branch, 
Galveston. All microsomal preparations were stored at – 80 °C until used. 
Methadone for IV administration was obtained from Xanodyne (Newport, KY) as 
a 10 mg/ml solution.  Volumes of methadone used for each administration were recorded 
as 0.6 ml (6 mg). This dose was diluted in 50 ml of normal saline for IV infusion. The 
same lot number was used for each administration of methadone, and was prepared by 
the Indiana University Hospital Pharmacy, Investigational Drug Services. Letrozole pills 
(Femara® 2.5 mg tablets) were obtained from Novartis (Basel, Switzerland).  
 
Testosterone and methadone metabolism in vitro by recombinant aromatase 
All incubations were carried out using incubation times and protein 
concentrations that were within the linear range for reaction velocity. Testosterone and 
methadone were dissolved in methanol and diluted with the same solvent to the required 
concentrations. Any methanol in the incubation tubes was removed by drying in speed 
vacuum before the incubation. All incubations contained recombinant human aromatase 
in 100 mM sodium phosphate buffer (pH = 7.4), with a NADPH-generating system (1.3 
mM NADP, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, and 0.4 U/ml glucose 6-
phosphate dehydrogenase) and various concentrations of aromatase substrate in a final 
volume of 250 μl. When inhibition of metabolism was tested, the tested inhibitor was 
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mixed with the substrate and was present at a range of concentrations during the 
incubation. The incubation mixture was prewarmed for 5 min at 37 °C, initiated by 
addition of the NADPH-generating system, and incubated at 37 °C. When testosterone 
was the substrate, final aromatase concentration used was 0.01 µM and the incubation 
time was 10 min. When methadone was the substrate, final aromatase concentration used 
was 0.05 µM and the incubation time was 30 min. All reactions were terminated by the 
addition of 20 µL of 60 % (w / v) perchloric acid, immediate vortex and then placing the 
tubes on ice. 
 
HPLC-UV assays for the quantifications of estradiol and EDDP formation 
All samples were extracted immediately after the incubation. First, 25 µL of 500 
µM norgestrol was added to each sample as an internal standard. The incubation mixture 
was centrifuged at 14,000 rpm for 5 min at room temperature. The supernatant layer was 
made alkaline by adding 500 µL of 1M glycine-NaOH buffer (pH 11.3) and extracted by 
adding 6 mL of ethyl acetate. This mixture was vortex-mixed for 10 seconds and then 
centrifuged at 26,000 rpm for 15 min. The organic layer was transferred to 13 × 100-mm 
glass culture tubes and evaporated to dryness. The resulting residue was reconstituted 
with mobile phase (50% 10mM monobasic potassium phosphate, 40% acetonitrile and 
10% methanol) and analyzed as described below immediately.  
High performance liquid chromatography (HPLC) assays with ultraviolet (UV) 
detection were developed for the quantification of testosterone conversion to estradiol 
and of methadone conversion to EDDP. The HPLC-UV system was comprised of a 
Waters (Milford, MA) model 510 HPLC pump and a Waters model 717 plus 
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autosampler, coupled with a Waters 486 tunable absorbance detector. The separation 
system consisted of a Zorbax SB-C18 column (4.6 × 150 mm, 3.5 µm particle size, 
Phenomenex, Torrance, CA), a Nova-Pak C18 Guard column (4 µm; Waters, Inc., 
Ireland). An isocratic elution was used to separate the compounds. The mobile phase 
consisted of 50% 10mM monobasic potassium phosphate, 40% acetonitrile and 10% 
methanol without PH adjustment. The eluate was introduced, at 0.8 ml/min to the UV 
detector with a run time of 25 min. Under these conditions, the retention times of 
letrozole, estradiol, EDDP, testosterone, methadone, norgestrol and EMDP were 
approximately 3, 8, 10, 12, 15, 20 and 35 min, respectively.  
Peak areas for each peak were obtained from an integrator, and peak area ratios 
with internal standard were calculated.  Standard curves were estimated by linear 
regression of peak area ratios. Quantification of samples was carried out by applying the 
linear regression equation of the standard curve to the peak area ratio.  The microsomal 
activity data represent individual data points or the mean of duplicate assays. The limit of 
quantification for estradiol was 2.5 pmol on column, with intra- and inter-day coefficients 
of variation of 2.4% and 5.3% respectively. The limit of quantification of EDDP was 5 
pmol on column, with intra- and inter-day coefficients of variation of 5.5% and 7.3% 
respectively.  
 
LC-MS/MS assays for plasma and urinary methadone, EDDP and EMDP  
HPLC with tandem mass spectrometry detection (LC-MS/MS) assays were 
developed for the quantification of plasma and urinary methadone and its major 
metabolites, EDDP and EMDP. Each plasma and urine sample (1 ml) was extracted by 
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adding 500 µL of 1M glycine-HCl buffer (pH 3.0) and 6 mL of methyl tert-butyl ether. 
Nevirapine (100 µl of 1 µg/ml) was added to each sample as an internal standard. This 
mixture was mixed on a reciprocal shaker (Eberbach, Ann Arbor, MI) for 5 min and then 
centrifuged at about 3,000 rcf for 15 min. The organic layer was transferred to 13 × 100-
mm glass culture tubes and evaporated to dryness. The resulting residue was 
reconstituted with mobile phase (50% 20 mM ammonium acetate and 50% acetonitrile 
without pH adjustment) and analyzed immediately. The LC-MS/MS assay was performed 
on an Applied Biosystems (Foster City, CA) model API 2000 triple-quadrupole mass 
spectrometer, coupled with a Shimadzu (Addison, IL) HPLC system consisting of a 
model LC-20AB binary solvent delivery pump and model SIL-20A HT autosampler. The 
separation system was composed of a Luna 3 μm C18-2 column (100 × 2.00 mm i.d.; 
Phenomenex, Torrance, CA) and a nitrile guard column (4 × 3.0 mm; Phenomenex). The 
eluate was introduced, without splitting, at 0.200 mL/min to the electrospray ionization 
source. The electrospray voltage was set at + 2500 mV and the dwell time at 100 ms per 
detection channel with unit mass resolution on the quadrupole 1 and 3 mass analyzers. 
Optimal gas pressures for all of the analytes were: nitrogen nebulizer gas 20.00 psi, 
turbo/heater gas 0.00 psi, curtain gas 20.00 psi and collision gas 2.00 psi. All data were 
collected in the positive ion mode with the temperature of the interface set at 450 °C. 
Under these conditions, nevirapine, methadone, EDDP and EMDP were detected at the 
retention times of approximately 3, 6, 5, and 10 min, respectively, and were quantified 
using m / z values (Q3 / Q1) at 226.0 / 267, 265.2 / 310, 234.1 / 278 and 220.2 / 264 
respectively. Peak areas for each peak were obtained, and peak area ratios with internal 
standard were calculated. Quantification of samples was carried out by applying the 
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linear regression equation of the standard curve to the peak area ratio. Each analytical run 
included calibration samples and quality control samples at the concentration range of 0.1 
- 200 ng/ml for methadone, EDDP and EMDP. Using these methods, the limits of 
quantification (LOQs) for methadone, EDDP and EMDP were 0.1, 0.2 and 0.1 ng/ml 
respectively, with intra-day and inter-day coefficients of variation of less than 5 % and 
less than 12 % respectively for all three compounds, when measured above the LOQs. 
 
HPLC-UV-fluorescence assays for plasma letrozole 
Plasma letrozole concentrations were measured using HPLC assays with 
ultraviolet and fluorescence detection as described below. Baseline plasma samples (200 
μl) were made alkaline by adding 500 µL of 1 M glycine-NaOH buffer (pH 11.3) and 
extracted by adding 6 mL of ethyl acetate. Desmethyldiazepam (100 μl of 1000 ng/ml) 
was used as internal standard. All samples were mixed, centrifuged and transferred as 
described above, and then reconstituted with mobile phase (70% 10 mM monobasic 
potassium phosphate, 30% acetonitrile, pH adjusted to 6.5) and analyzed immediately. 
The HPLC system was controlled by CLASS-VP version 7.1.1 SP1 Chromatographic 
Software (Shimadzu Scientific Instruments Inc., Columbia, MD) and included a 
Shimadzu solvent delivery module SCL-10A VP, an autoinjector SIL-10AD VP, a 
spectrofluorometric detector RF-10A XL (set at an excitation wavelength of 230 nm and 
emission wavelength of 295 nm), an ultraviolet detector SPD-10A VP (set at a 
wavelength of 234 nm, 0.1 AUFS) and a system controller SCL-10A VP (Shimadzu, 
Kyoto, Japan). The eluate was directed at 1 ml/min through a Zorbax SB-C18 3.5-μm C18 
column (150 × 4.6 mm i.d.; Agilent Technologies, Santa Clara, CA) coupled with a 
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Nova-Pak C18 Guard column (4 μm; Waters, Inc., Ireland) with a run time of 32 min. 
Under these conditions, the retention times of letrozole and desmethyldiazepam were 
approximately 17 and 27 min, respectively. The limit of quantification for letrozole was 
12.5 ng/ml, with intra-day and inter-day coefficients of variation of less than 4.3% and 
less than 8.1% respectively. 
 
Fluorescent assay for inhibition of aromatase in vitro 
The activity of recombinant human aromatase was determined by measuring the 
conversion rate of a fluorometric substrate, 7-methoxy-4-trifluoromethylcoumarin 
(MFC), to its fluorescent metabolite, 7-hydroxytrifluoromethylcoumarin (HFC). 
Experimental procedures were consistent with the methodology described for high-
throughput screening of a human cytochrome P450 inhibitor (Stresser 2004). All 
incubations were carried out using incubation times and protein concentrations that were 
within the linear range for reaction velocity. Experiments involving tamoxifen and its 
metabolites were carried out under dim light to minimize photodegradation. MFC and 
inhibitors were prepared in acetonitrile solutions. A series of concentrations of inhibitor 
in a volume of 4 µl were mixed with 96 µl of NADPH-Cofactor Mix (16.3 µM NADP, 
828 µM glucose-6-phosphate, 828 µM MgCl2, and 0.4 U/ml glucose 6-phosphate 
dehydrogenase), and prewarmed for 10 min at 37 °C. MFC and recombinant human 
aromatase were mixed with 0.1 M potassium phosphate buffer (pH 7.4), and then added 
to an Enzyme/Substrate Mix. Reactions were initiated by adding 100 µl of Enzyme / 
Substrate Mix to bring the incubation volume to 200 µl. Final MFC concentration was 
typically set at 25 µM. When multiple substrate concentrations were tested in order to 
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characterize detailed kinetics of enzyme inhibition, final MFC concentrations of 10, 15, 
20 and 25 µM were used. Final recombinant aromatase concentration was 7.5 nM. After 
incubation for 30 min at 37 °C, all reactions were stopped by adding 75 µl of acetonitrile 
/ 0.1 M tris base. When aromatase inhibition was tested using human placental 
microsomes, experimental conditions were the same as described above except that the 
final total protein concentration was 0.12 mg/ml. The generation of HFC was determined 
immediately by measuring fluorescence response (excitation 400 nm, emission 540 nm) 
using a BioTek (Winooski, VT) Synergy 2 fluorometric plate reader. The activity of 
placental human aromatase was determined using the same methods with the exception 
that final protein concentration was 0.06 mg/ml. Standard curves were constructed using 
fluorescent metabolite HFC standard. Quantification of samples was carried out by 
applying the linear regression equation of the standard curve to the fluorescence 
response. The limit of quantification for HFC was 0.02 µM in a final volume of 200 µl, 
with intra- and inter-day coefficients of variation of 6.2% and 8.4% respectively.  
 
Mechanism-based inhibition of aromatase in vitro 
Recombinant aromatase was preincubated with various concentrations of tested 
inhibitor. All preincubations contained tested inhibitor, 0.1 µM aromatase and 100mM 
sodium phosphate buffer (pH = 7.4), NADPH-generating system (1.3 mM NADP, 3.3 
mM glucose-6-phosphate, 3.3 mM MgCl2, and 0.4 U/ml glucose 6-phosphate 
dehydrogenase) in a final volume of 250 μl. Preincubations were initiated and carried out 
in the same way as described for the microsomal incubation conditions described above. 
After a period of time, each 250 μl preincubation mixture was diluted 10 times with a 
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solution containing testosterone, sodium phosphate buffer and NADPH-generating 
system to reach a final incubation mixture of 50 µM testosterone and 0.01 µM aromatase. 
The dilution was to eliminate competitive inhibition as a possible cause of the inhibitory 
effect. This incubation mix was then incubated at 37 °C for 10 min. The reaction was 
terminated the same way as described above. The extent of inactivation of aromatase, 
expressed as the percent activity remaining after preincubation, was determined by 
measuring the conversion rate of testosterone to estradiol.  
 
Inhibition of testosterone metabolism by aromatase in vitro 
The activity of aromatase was determined by measuring the rate of conversion of 
testosterone to estradiol. All incubations were carried out using incubation times and 
protein concentrations that were within the linear range for reaction velocity. 
Testosterone and the tested inhibitors were prepared in methanol. All experiments were 
performed under dim light and in brown, gall tubes to minimize photodegradation of 
tamoxifen and its metabolites.  
For reversible inhibition studies, testosterone and inhibitor were mixed at the 
appropriate concentrations, and methanol was removed by drying under speed vacuum 
before the incubation. All incubations contained recombinant human aromatase in 100 
mM sodium phosphate buffer (pH 7.4), with a NADPH-generating system (1.3 mM 
NADP, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, and 0.4 U/ml glucose 6-phosphate 
dehydrogenase) in a final volume of 250 μl. The reaction was prewarmed for 5 min at 37 
°C, initiated by the addition of the NADPH-generating system, and incubated at 37 °C for 
10 min. Final aromatase concentration was 50 nM. Final testosterone concentrations of 1, 
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2, 4 and 8 µM were tested. All reactions were terminated by the addition of 20 μl of 60% 
(w / v) perchloric acid, followed by immediate vortexing and placement of the tubes on 
ice. The fluorometric substrate, MFC was tested under these same conditions in order to 
compare IC50 values of tested inhibitors with a different substrate. For studies designed to 
test for irreversible inhibition, experiments were carried out as described above in 
“Mechanism-based inhibition of aromatase in vitro”. 
 
Inhibition of recombinant human CYP isoforms  
The activity of each recombinant human CYP isoform was determined by 
measuring the conversion rate of a fluorometric substrate to its fluorescent metabolite. 
Aromatase and CYP2C9 activities were determined using the metabolism of 7-methoxy-
4-trifluoromethylcoumarin (MFC) to 7-hydroxytrifluoromethylcoumarin. CYP2C19 
activity was determined using the metabolism of 3-cyano-7-ethoxycoumarin (CEC) to 3-
cyano-7-hydroxycoumarin. CYP2D6 activity was determined using the metabolism of 3-
[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC) to 3-[2-
(N,N-diethylamino)ethyl]-7-methoxy-4-methylcoumarin. Experimental procedures were 
consistent with the published methodology (Stresser 2004). All incubations were carried 
out using incubation times and protein concentrations that were within the linear range 
for reaction velocity. Substrates and inhibitors were prepared in acetonitrile. A series of 
concentrations of inhibitor in a volume of 4 µl were mixed with 96 µl of NADPH-
Cofactor Mix (16.3 µM NADP, 828 µM glucose-6-phosphate, 828 µM MgCl2, and 0.4 
U/ml glucose 6-phosphate dehydrogenase), and prewarmed for 10 min at 37 °C. Enzyme 
/ Substrate Mix was prepared with fluorometric substrate, recombinant human CYP 
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isoform and 0.1 M potassium phosphate buffer (pH 7.4). Reactions were initiated by 
adding 100 µl of Enzyme/Substrate Mix to bring the incubation volume to 200 µl. The 
optimal final recombinant enzyme concentrations, substrate concentrations and 
incubation times were: 7.5 nM AROMATASE + 25 µM MFC for 30 min, 15 nM 
CYP2C9 + 150 µM MFC for 45 min, 7.5 nM CYP2C19 + 25 µM CEC for 30 min, and 
7.5 nM CYP2D6 + 1.5 µM AMMC for 30 min. All reactions were stopped by adding 75 
µl of acetonitrile / 0.1 M tris base. The generation of fluorescent metabolites was 
determined immediately by measuring fluorescent response using a BioTek (Winooski, 
VT) Synergy 2 fluorometric plate reader. Excitation - emission wavelengths were 400 - 
540 nm for the MFC metabolite or 400 - 460 nm for the CEC and AMMC metabolites. 
Standard curves were constructed using the appropriate fluorescent metabolite standards. 
Quantification of samples was carried out by applying the linear regression equation of 
the standard curve to the fluorescence response. The limits of quantification for the 
metabolites of MFC, CEC and AMMC were 4 pmol, 0.1 pmol and 0.8 pmol in a final 
volume of 200 µl respectively, with intra- and inter-assay coefficients of variation of less 
than 10%.  
 
Inhibition of specific CYP isoforms using pooled HLMs 
Inhibition of individual CYP isoforms was studied as previously described (Jeong 
et al. 2009) with the modification that the formation rates of 4-hydroxybupropion from 
bupropion, of 5′-hydroxyomeprazole from omeprazole and of 6-β hydroxytestosterone 
from testosterone served as markers of CYP2B6, CYP2C19 and CYP3A activity 
respectively. A single isoform-specific substrate concentration at the respective Km value 
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was incubated at 37 °C in duplicate with pooled HLMs and the a NADPH-generating 
system (1.3 mM NADP, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, and 0.4 U/ml 
glucose 6-phosphate dehydrogenase) in the absence or the presence of tested inhibitors. 
The activity of specific CYP isoform was determined by measuring the formation rate of 
corresponding metabolite from probe drug in pooled HLMs. All incubations were carried 
out using incubation time and protein concentrations that were within the linear range for 
reaction velocity. An incubation mixture that consisted of substrate probes, HLMs, and 
100 mM phosphate reaction buffer (pH 7.4) was pre-warmed for 5 min at 37 °C. The 
reaction was initiated by the addition of the NADPH-generating system, and incubated at 
37 °C for 15 min. The final protein concentration of pooled HLMs was 0.25 mg/ml. All 
reactions were terminated by the addition of 500 μl of acetonitrile, followed by 
immediate vortex and placement of the tubes on ice. All samples were extracted 
immediately after the incubations were carried out. The quantification methods for 
metabolite formation were the same as those described in published papers (Jeong et al. 
2009; Lu, Ferlito et al. 2011; Lu, Xu et al. 2011). 
 
Computerized molecular modeling 
“All tamoxifen metabolite structures were constructed with Sybyl 7.1 software 
and their energies minimized to 0.01 kcal/mol by the Powell method, using Gasteiger-
Hückel charges and the Tripos force field. The energy-minimized structures were docked 
into the androgen binding pocket in aromatase after removal of the structure of the 
natural ligand. The parameters were set as the default values for protein-ligand docking 
program GOLD. The maximum distance between hydrogen bond donors and acceptors 
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for hydrogen bonding was set to 3.5 Å. After docking, the lowest-energy docking 
solutions of compounds of interest were merged into the ligand–free protein structure. In 
the case of (Z)-norendoxifen, the amino side chain was rotated manually to place the 
nitrogen atom within hydrogen bonding distance to the Ala306 carbonyl oxygen, which 
ultimately resulted in a more favorable calculated binding energy after energy 
minimization. The structures of the new ligand–protein complexes were subsequently 
subjected to energy minimization using the Amber force field with Amber charges. 
During the energy minimizations, the structures of the compounds of interest and a 
surrounding 10 Å sphere of the protein were allowed to move. The structure of the 
remaining protein was kept frozen. The energy minimizations were performed using the 
Powell method with a 0.05 kcal/(mol Å) energy gradient convergence criterion and a 
distance-dependent dielectric function.” Note: Described by co-investigators in Mark 
Cushman Lab at Purdue University; quoted from (Lu, Xu et al. 2011).  
 
Protocol for clinical trial: effects of aromatase inhibition on methadone disposition 
Specific Aim:  
To test the hypothesis that methadone is significantly metabolized by aromatase 
in vivo by measuring single dose methadone pharmacokinetics in healthy post-
menopausal female volunteers in the presence and absence of the selective aromatase 
inhibitor letrozole. 
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Research Design:  
This study will be conducted at the Indiana University School of Medicine 
Clinical Research Center (ICRC). This is a single-site, acute-dose and three-period design 
to determine the effect of the administration of the aromatase inhibitor letrozole given at 
a dose of 2.5 mg daily by mouth for 7 days, on single dose methadone pharmacokinetics. 
The specific procedures to be carried out and their sequence in time are detailed in Figure 
3.4. 
Letrozole specifically and potently reduces the activity of aromatase, with its 
maximal effect on serum estrogen concentration being evident after five days (FDA 
letrozole label). We therefore conservatively anticipate that aromatase will be completely 
inhibited after 7 days of treatment. 
Previous investigators studying drug interactions with methadone have 
successfully used a single dose of intravenous racemic methadone (6.0 mg, 5.4 mg free 
base) administered intravenously, followed by pharmacokinetic sampling for the 
measurement of serum methadone concentrations for 96 hours after the dose, using 
sampling at 30 min, and then 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after the dose in 
normal volunteers. Since the terminal elimination phase of methadone clearance can be 
accurately estimated by 72 hours, we will use a pharmacokinetic sampling strategy 
involving collections of blood between 0 and 72 hours. In this particular study we will be 
administering 2 mg of methadone IV.  After methadone has been cleared from the body, 
daily dosing of letrozole will begin on the 8th day after the first methadone dose. The 
same procedure involving a single intravenous dose of methadone will be repeated on the 
15th day of the study after pretreatment with letrozole for 7 days.  
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Patient Selection: 
A total of 15 normal volunteers who satisfy the inclusion and exclusion criteria 
below will be enrolled in this trial after a prescreening visit.  
Inclusion Criteria: 
1. Subjects must weigh at least 110 pounds. 
2. 45 - 70 years of age. 
3. Post-menopausal as defined by more than one year without menses, or after 
surgical oophorectomy. For women who have undergone a partial surgical 
hysterectomy and are age 55 or less, an estradiol level will be done to confirm 
post menopausal status. 
4. Subjects must be capable of satisfying protocol requirements and be able to 
provide written informed consent.  
5. Agree to avoid the use of alcohol during the period of the study. 
Exclusion Criteria: 
1. Subjects must not have a history of intolerance or allergy to the study drugs: 
methadone or letrozole.  
2. A diagnosis of asthma, chronic obstructive pulmonary disease or cor pulmonale, 
severe obesity with a weight over 300 lbs, or sleep apnea syndrome. 
3. Renal insufficiency as indicated by a serum creatinine greater than 1.4.  
4. Anemia as defined by a hematocrit of below 30%. 
5. Elevation of serum liver enzymes outside the normal range indicating clinically 
significant hepatic dysfunction.  
6. Subjects with low serum potassium and magnesium levels. 
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7. Have donated blood to the blood bank within the last 2 months. 
8. Have taken part in an investigational drug research study within the last 2 months. 
9. Increased electrocardiographic QT interval as measured by a QTc (Bazette) of 
more than 480 msecs.  
10. Subjects taking drugs that are known to possibly prolong the QT interval. 
 
Study Procedures: 
Screening: After a signed written informed consent is obtained from the subject, a 
detailed health history will be collected in addition to blood collection, vital signs and a 
12 lead electrocardiogram. 10 cc of blood will be collected for genotyping, CBC/diff/plts, 
Comprehensive Metabolic Panel and serum estradiol. Since methadone has been 
associated with prolongation of the QT interval when given at high doses intravenously, 
and there are clear FDA reports of torsades de pointes arrhythmia in patients treated with 
methadone, a resting electrocardiogram will be obtained to ensure that patients are not 
placed at risk for arrhythmia by a prolonged baseline electrocardiographic QT interval. 
The screening will be carried out no later than 4 weeks prior to the study. 
Period 1 (Control): Once the screening is completed, qualifying subjects will be 
admitted to the ICRC at about 7 AM for approximately 25 hours (day 1), after an 
overnight fast of at least  8 hours. 
Following predose blood and urine sampling, and the insertion of a forearm 
intravenous catheter, subjects will be administered 250 cc of normal saline and then will 
receive methadone 2.0 mg (5.4 mg free base) IV.  After methadone administration, eight 
samples of blood (~ 10 cc each) will be collected over the next 72 hours according to the 
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following schedule: 1, 2, 4, 8, 12, 24, 48, and 72 hours after the dose. After the 24 hour 
sample has been collected, patients will be discharged from the unit. Subjects will be 
instructed to return again at 48 and 72 hours after the dose for additional single blood 
draws. Upon return for the 48 and 72 hour blood draws, subjects will be asked to return 
within a window of plus or minus 2 hours from the assigned time. Similarly the 12 hour 
urine collection will be stopped at 12 hours after methadone dosing and the exact time of 
the last urine collection will be recorded. At the 72 hour visit, patients will be given an 11 
day supply of letrozole, to be taken daily starting on Day 8, and continuing through Day 
18. They will be instructed to take a single dose of letrozole (2.5 mg) each morning at the 
same time starting on Day 8, and to return to the ICRC at approximately 7 AM on Day 15 
for approximately 25 hours after an overnight fast of at least 8 hours. 
Methadone Washout: Patients will not return to the ICRC until Day 15. In the 
interim, they will simply begin talking letrozole tablets once daily beginning on Day 8. 
Period 2 (Letrozole Treatment):  The same procedures as described above for Day 
1 - 4 will be carried out on Day 15 - 18 of the study, except that patients will continue to 
take a single letrozole tablet every morning until Day 18, when the last dose of letrozole 
will be taken in the morning. Note: On Day 15, subjects will be asked to hold their 
letrozole dosing until their arrival to the ICRC and will then be given the letrozole an 
hour after the methadone dose that day. In order to assess patient compliance with daily 
letrozole dosing, the blood drawn immediately before the dose of methadone on Day 15 
will be used to measure letrozole serum concentrations. Since methadone has highly 
variable inter-individual clearance, serum methadone concentrations will also be 
159 
 
measured in the blood samples obtained on Day 15 to ensure that no methadone remains 
in the blood before the pharmacokinetic sampling done in period 2. 
Subjects who withdraw from the study or are terminated per investigator’s 
discretion will be replaced for a total of 15 normal volunteers who have completed all 18 
days of the study.   
Study Drugs: Methadone will be supplied by the Indiana University Hospital 
Inpatient Pharmacy. A single batch of letrozole 2.5 mg pills to be used for the whole 
study will also be purchased from the Indiana University Hospital Pharmacies.   
 
Statistics:  
Statistical comparisons between the 15 subjects at baseline and after letrozole 
administration for each of the following serum methadone pharmacokinetic indices will 
be carried out:  AUC, AUCinf, terminal elimination half life, clearance and clearance/kg 
will be compared between the two periods using a paired student’s t-test. The ratios of the 
urinary concentrations of EDDP and EMDP to urinary methadone will also be compared 
between the two periods using a paired student’s t-test.  
Power: Using this design with 15 patients, and a coefficient of variation of 40% in 
the AUC of this dose of intravenous methadone, and using a two-tailed paired-test, we 
will have 90% power to detect a change of 33% or more in the AUC of methadone, with 
an α of 0.05. Such a 33% change would indicate that aromatase is responsible for 33% of 
methadone clearance. 
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Procedures to Minimize the Potential Risks of This Study: 
1. An electrocardiogram will be performed as part of screening, and subjects with 
abnormal electrocardiograms will be excluded from the study. 
2. Phlebotomy will follow approved hospital and/or nursing policies and procedures. 
3. Trained personnel will perform blood and urine sampling. 
4. Prior to administration of methadone, subjects will be given 250 cc of normal 
saline. 
5. All subjects will be under close supervision by medical staff. 
6. Adverse events will be evaluated & treated immediately, if necessary. 
7. Parameters for Narcan adminstration will be included in the doctor’s orders which 
are different than Clarian’s standard Narcan policy,  These parameters will offer a 
more sensitive reaction to methadone overdose and will be specific only to this 
study.  They include: 
a. If RR <10, add O2 to keep O2 sats > 92%. 
b. If RR <8 or O2 sats < 90%, administer Narcan. 
c. If Narcan is administered, subject will be assessed by a physician at time 
of adminstration as well as every hour until stable. 
d. If Narcan is administered, continue VS every 10 minutes until stable. 
8. Although methadone does not meet Clarian’s definition of ‘conscious sedation’, 
we will initiate the ‘conscious sedation’ policy which includes continuous pulse 
ox monitoring as well as frequent VS assessments. 
9. Subject will be required to be seen and assessed by a physician prior to discharge. 
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10. Subjects will be required to spend the night on Day 1 and 15. Prior to discharge 
the next morning, subject will be assessed by a physician and then released to self 
per MD approval. 
11. Information in the study records will be kept confidential. Any reporting of data 
will not include subject names. This information will not be given to any 3rd party 
or used for other purposes without the written permission of the subject. 
Note: Modified from Indiana University IRB approved protocol which I co-wrote 
(Flockhart and Lu 2010). 
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